WO2018029890A1 - Antibiotic - Google Patents

Antibiotic Download PDF

Info

Publication number
WO2018029890A1
WO2018029890A1 PCT/JP2017/012319 JP2017012319W WO2018029890A1 WO 2018029890 A1 WO2018029890 A1 WO 2018029890A1 JP 2017012319 W JP2017012319 W JP 2017012319W WO 2018029890 A1 WO2018029890 A1 WO 2018029890A1
Authority
WO
WIPO (PCT)
Prior art keywords
dimethyl sulfoxide
weight
solution
vitamin
cells
Prior art date
Application number
PCT/JP2017/012319
Other languages
French (fr)
Japanese (ja)
Inventor
靖史 田中
Original Assignee
株式会社ブレインヘルス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社ブレインヘルス filed Critical 株式会社ブレインヘルス
Publication of WO2018029890A1 publication Critical patent/WO2018029890A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13Coniferophyta (gymnosperms)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses

Definitions

  • the present invention relates to antibiotics.
  • Patent Document 1 discloses an agent for preventing influenza virus infection.
  • the preventive agent for influenza virus infection disclosed in Patent Document 1 uses tea leaves as an active ingredient.
  • the influenza virus infection preventive agent disclosed in Patent Document 1 can effectively prevent virus infection without depending on antigenicity, and has no harmful side effects on the human body.
  • Patent Document 2 discloses a pharmaceutical composition.
  • the pharmaceutical composition disclosed in Patent Document 2 contains a modified catechin.
  • the pharmaceutical composition disclosed in Patent Document 2 can increase antibacterial activity.
  • the preventive agent for influenza virus infection disclosed in Patent Document 1 and the pharmaceutical composition disclosed in Patent Document 2 have a problem in that the onset of the effect is slow.
  • the object of the present invention is to provide antibiotics that are effective quickly.
  • antibiotics containing melinjo extract and vitamin E can quickly suppress the activity of bacteria and viruses, and completed the present invention.
  • the present invention relates to antibiotics.
  • This antibiotic includes gnetin C, resveratrol, vitamin E, and a fluidizing substance.
  • the weight% of gnetin C is 0.17 wt% or more and 4.11 wt% or less.
  • the weight% of resveratrol is 0.06 wt% or more and 1.33 wt% or less.
  • the weight% of vitamin E is 0.28 wt% or more and 2.22 wt% or less.
  • the weight% of the above-mentioned gnetin C is 0.17 wt% or more and 1.37 wt% or less.
  • the weight% of resveratrol is 0.06 weight% or more and 0.44 weight% or less.
  • the sum of the weight% of the above-mentioned gnetin C and the weight% of resveratrol is 0.23% by weight or more and 1.81% by weight or less.
  • the weight% of the above-mentioned gnetin C is 0.17 wt% or more and 0.69 wt% or less.
  • the weight% of resveratrol is 0.06 weight% or more and 0.22 weight% or less.
  • the antibiotic of the present invention is effective quickly.
  • MDCK. 2 When the cells were placed in the collagen gel coat preparation indentation, the MDCK. It is a microscope picture of 2 cells. MDCK. 2 When the cells were put into the collagen gel coat preparation indentation, the MDCK. It is a microscope picture of 2 cells. MDCK. The MDCK.2 at 100 minutes after the 2 cells were placed in the preparation of the collagen gel coat preparation. It is a microscope picture of 2 cells. MDCK. 2 When the cells were placed in the collagen gel coat preparation indentation 120 minutes later, the MDCK. It is a microscope picture of 2 cells. MDCK. 2 When the cells were placed in the collagen gel coat preparation indentation 150 minutes later, their MDCK. It is a microscope picture of 2 cells. MDCK.
  • MDCK. 2 When the cells were placed in the collagen gel coat preparation indentation, the MDCK. It is a microscope picture of 2 cells. MDCK. 2 When the cells were put into the collagen gel coat preparation indentation, the MDCK. It is a microscope picture of 2 cells. MDCK. 2 When the cells were placed in the collagen gel coat preparation indentation 120 minutes later, the MDCK. It is a microscope picture of 2 cells. MDCK. 2 MDCK. Of the cells at the time when 180 minutes have passed since the cells were put into the preparation of the collagen gel coat preparation. It is a microscope picture of 2 cells. MDCK. It is the figure which showed the microscope picture of 2 cells along the time series.
  • Antibiotics of the present invention include gnetin C, resveratrol, vitamin E, and a fluidizing substance.
  • Gnetin C is a dimer of resveratrol.
  • the structural formula of gnetin C is well known and will not be repeated here.
  • Gnetin C is contained, for example, in the fruit of Merinjo (scientific name: Gnetum gnemon).
  • the weight% of gnetin C is 0.17 wt% or more and 4.11 wt% or less.
  • the weight% of gnetin C is 0.17 wt% or more and 1.37 wt% or less. More preferably, the weight% of gnetin C is 0.17 wt% or more and 0.69 wt% or less.
  • Resveratrol is a kind of stilbene derivative. The structural formula of resveratrol is well known and will not be repeated here. Resveratrol is found in red wine, red grape skin, peanut skin, itadori, melinjo and others.
  • the weight percent of resveratrol is 0.06 wt% or more and 1.33 wt% or less. Preferably, the weight percent of resveratrol is 0.06 wt% or more and 0.44 wt% or less. More preferably, the weight percent of resveratrol is 0.06 wt% or more and 0.22 wt% or less.
  • the weight% of gnetin C is 0.17 wt% or more and 1.37 wt% or less and the weight% of resveratrol is 0.06 wt% or more and 0.44 wt% or less, It is preferable that the sum of the weight percent of the above and the weight percent of resveratrol is 0.23% by weight or more and 1.81% by weight or less.
  • the vitamin E weight percent is 0.28 wt% or more and 2.22 wt% or less.
  • the vitamin E weight percent is 0.28 wt% or more and 1.11 wt% or less.
  • the fluidizing substance is a substance that facilitates the flow of the antibiotic of the present invention.
  • the specific components of the fluidizing substance are not particularly limited as long as the synergistic effects of gnetin C, resveratrol, and vitamin E are not completely lost.
  • the fluidizing substance is preferably a substance that does not impair the synergistic effect of gnetin C, resveratrol, and vitamin E.
  • the fluidizing substance is more preferably a substance that enhances the synergistic effect of gnetin C, resveratrol, and vitamin E.
  • Examples of fluidizing materials include dimethyl sulfoxide and purified water.
  • Antibiotics of the present invention may contain components other than gnetin C, resveratrol, vitamin E, and fluidizing substances.
  • An example of such a component is Gnetin C glycoside.
  • glycosides of gnetin C include gunemonoside A, gunemonoside C, and gunemonoside D.
  • the specific content of such components is not particularly limited as long as the synergistic effect of gnetin C, resveratrol, and vitamin E is not completely lost.
  • the antibiotic of the present invention may consist only of gnetin C, resveratrol, vitamin E, and a fluidizing substance.
  • the method for producing the antibiotic of the present invention is not particularly limited.
  • One example includes an extract extraction process, a fruit crushing process, a vitamin E addition process, and a fluidization process.
  • the extract extraction step is a step of extracting the meringo extract from the fruit of meringo.
  • Melinjo extract is an extract of the fruit of Merinjo.
  • Melinjo extract contains gnetin C and resveratrol.
  • the fruit crushing step is a step of crushing the fruit of Merinjo.
  • Merinjo fruit is pulverized before the meringo extract is extracted from merinjo fruit in the extract extraction process.
  • the vitamin E addition step is a step of adding vitamin E to the meringo extract after the extract extraction step.
  • the fluidizing step is a step of imparting fluidity to the meringo extract.
  • the antibiotic according to the present invention can be used for various applications described below. Its uses are the control of bacteria and viruses, their disinfection, and their growth inhibition. The range of bacteria and viruses targeted by the antibiotic according to the present invention is not particularly limited. Antibiotics according to the present invention can combat various bacteria and various viruses. The antibiotic according to the present invention can be used in various ways. Examples include internal medicines, paints, poultices, and sprays.
  • Example 1 (1) Test Procedure (A) Preparation of Melinjo Extract Tube
  • the worker prepared a Melinjo extract tube.
  • the “merinjo extract tube” is a tube in which a purified merinjo extract solution described later is contained in a predetermined tube described later.
  • the operator prepared the meringo extract tube according to this example according to the following procedure. First, the worker roasted the fruit of Melinjo (scientific name: Gnetum gnemon) at 110 degrees Celsius for 10 minutes. The mass of merinjo fruit for one meringo extract tube was 50 grams. By roasting, the water content of the melinjo was 8% by weight. The meringo was made by pulverizing the whole skin, fruit and seeds.
  • the operator When the roasting was finished, the operator soaked the roasted melinjo in 55% by weight ethyl alcohol in a sealed bottle for 24 hours.
  • the volume of ethyl alcohol for one meringo extract tube was 500 ml. While the meringo was soaked, the temperature of the ethyl alcohol was maintained at 90 degrees Celsius. While the meringo was soaked, the ethyl alcohol continued to be stirred by the stirrer. After the meringo was soaked in ethyl alcohol for 24 hours, the worker extracted an unpurified meringo extract from the ethyl alcohol supernatant.
  • a centrifugal evaporator (EC-57C manufactured by Sakuma Seisakusho Co., Ltd.) was used for extraction of the unpurified melinjo extract.
  • the extraction time was 12 hours.
  • the unpurified meringo extract extracted by the centrifugal evaporator was in the form of a dry powder.
  • the worker added an aqueous dimethyl sulfoxide solution (the concentration of dimethyl sulfoxide was 63% by weight) to the unpurified melinjo extract and stirred.
  • the amount of the aqueous dimethyl sulfoxide solution added was 3 ml with respect to 5 ml of the supernatant of ethyl alcohol from which the unpurified meringo extract was extracted.
  • the unpurified meringo extract to which the aqueous dimethyl sulfoxide solution has been added and stirred is the unpurified meringo extract solution in this example.
  • the operator removed impurities from the unpurified melinjo extract solution by using a centrifuge (Eppendorf Model 5415R). The rotational speed of this centrifuge was 15400 rpm. This centrifuge was used for 10 minutes. By removing the impurities, the unpurified meringo extract solution became a purified meringo extract solution.
  • the purified meringo extract solution contained in one meringo extract tube is composed of 0.46% by weight of gnetin C, 0.15% by weight of resveratrol, 62.62% by weight of dimethyl sulfoxide, and water content. 36.77% by weight.
  • (B) Preparation of vitamin tube The operator put 50 grams of vitamin E powder (manufactured by Yamaguchi Kaken Co., Ltd.) into a bottle. The worker then placed 500 ml of ethyl alcohol (concentration 55% weight) in the bottle. Thereby, the powder of vitamin E is immersed in the ethyl alcohol. The powder was immersed in the ethyl alcohol for 12 hours while sealed in the bottle. Meanwhile, the temperature of ethyl alcohol was 80 to 90 degrees Celsius. Meanwhile, the powder and the ethyl alcohol were stirred with a stirrer. Thereafter, the worker left the mixture for 12 hours. After 12 hours, a thin oil film was formed on the surface of the mixture.
  • vitamin E powder manufactured by Yamaguchi Kaken Co., Ltd.
  • the oil film is purified vitamin E (hereinafter referred to as “purified vitamin E”).
  • purified vitamin E The worker accommodated 10 milligrams (20 milliliters) of this purified vitamin E in a predetermined tube.
  • This tube is the same type of tube used for the preparation of melinjo extract tubes.
  • the tube containing 10 milligrams of purified vitamin E is a vitamin tube.
  • the volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml.
  • This mixed liquid is a sample according to this example. Therefore, the components of the sample according to this example are as follows: gnetin C 1.37% by weight, resveratrol 0.44% by weight, dimethyl sulfoxide 60.46% by weight, vitamin E 2.22% by weight, moisture Is 35.51% by weight.
  • (C) Preparation of liquid medium First, the operator added the following seven kinds of substances to 1 liter of sterilized purified water (manufactured by ASONE CORPORATION).
  • the first substance is 10 grams of powder medium (Wako Pure Chemical Industries, E-MEM Powder, product number 054-09001).
  • the second substance is the serum of a newborn calf within 10 days after birth (product number 04-102-1A, manufactured by Cosmo Bio Inc.).
  • the operator added 100 ml of this serum to the sterile purified water described above.
  • the third substance is penicillin streptomycin (manufactured by Wako Pure Chemical Industries, Ltd., product number 168-23191). The amount of penicillin / streptomycin added was 10 ml.
  • the fourth substance is a vitamin solution (Wako Pure Chemical Industries, Ltd., MEM vitamin solution, product number 130-17141). The amount of vitamin solution added was 10 ml.
  • the fifth substance is a non-essential amino acid solution (Wako Pure Chemical Industries, Ltd., MEM non-essential amino acid solution, product number 139-15651). The amount of the non-essential amino acid solution added was 10 ml.
  • the sixth substance is a sodium pyruvate solution (manufactured by Wako Pure Chemical Industries, Ltd., sodium pyruvate solution, product number 190-14881). The amount of this sodium pyruvate solution added was 10 ml.
  • the seventh substance is 13.4 grams of sodium bicarbonate (Wako Pure Chemical Industries, Ltd., product number 198-01315).
  • sodium bicarbonate Wood Chemical Industries, Ltd., product number 198-01315
  • the operator agitated the sterilized purified water with the substances added.
  • Stirred sterilized purified water is the liquid medium according to this example. In the following description, this liquid medium is referred to as “liquid medium”.
  • Example 2 (1) Test procedure An operator shall prepare 13.5 ml of purified meringo extract solution contained in nine meringo extract tubes and purified vitamin E contained in one vitamin tube in a test tube. Dissolved in dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 18 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml.
  • This mixed liquid is a sample according to this example. Therefore, the components of the sample according to this example are 4.11% by weight of gnetin C, 1.33% by weight of resveratrol, 58.17% by weight of dimethyl sulfoxide, 2.22% by weight of vitamin E, moisture Is 34.17% by weight. Other points are the same as in the first embodiment.
  • Example 3 (1) Test procedure The operator puts 4.5 ml of purified merinjo extract solution contained in three meringo extract tubes and purified vitamin E contained in one vitamin tube in a test tube. Dissolved in dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml.
  • Example 4 (1) Test procedure The operator puts 4.5 ml of purified merinjo extract solution contained in three meringo extract tubes and purified vitamin E contained in one vitamin tube in a test tube. Dissolved in dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml.
  • Example 5 (1) Test procedure The operator puts 4.5 ml of purified merinjo extract solution contained in three meringo extract tubes and purified vitamin E contained in one vitamin tube in a test tube. Dissolved in dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml.
  • Example 6 (1) Test procedure In preparation of the sample, the operator tested nine meringo extract tubes (18 grams of purified meringo extract solution) and purified vitamin E (10 milligrams) contained in one vitamin tube. It was dissolved in 13.5 ml dimethyl sulfoxide stock solution in a tube. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 18 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml.
  • the volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml.
  • This mixed liquid is a sample according to this example. Therefore, the components of the sample according to this example are 4.11% by weight of gnetin C, 1.33% by weight of resveratrol, 58.17% by weight of dimethyl sulfoxide, 2.22% by weight of vitamin E, moisture Is 34.17% by weight.
  • the operator placed MDCK. Two cells were added. This MDCK. Two cells were cultured in 20 microliters of liquid medium. This MDCK. Two cells were placed in the wells along with the liquid medium. MDCK. After 60 minutes have passed since the two cells were placed in the preparation, the operator can then confirm the MDCK. Two cells were loaded with 20 microliters of the liquid described below.
  • the liquid contained RS virus (ATCC number VR-1580). As a result, the MDCK. Two cells were infected with RS virus. Other points are the same as in the first embodiment.
  • FIG. 1 shows MDCK. 2 When the cells were placed in the collagen gel coat preparation indentation, the MDCK. It is an optical micrograph of 2 cells.
  • FIG. 2 shows MDCK. 2 When 70 minutes have passed since the cells were placed in the preparation of the collagen gel coat preparation (when 10 minutes have passed since infection with the RS virus), the MDCK. It is an optical micrograph of 2 cells.
  • FIG. 3 shows MDCK. 2 When 100 minutes have passed since the cells were placed in the preparation of the collagen gel coat preparation (when 40 minutes have passed after infection with the RS virus), the MDCK. It is an optical micrograph of 2 cells.
  • FIG. 4 shows MDCK.
  • FIG. 5 shows MDCK.
  • the MDCK.2 at the time when 150 minutes have passed since the 2 cells were placed in the preparation of the collagen gel coat preparation (90 minutes after infection with the RS virus). It is an optical micrograph of 2 cells.
  • FIG. 6 is a block diagram of MDCK. It is the figure which showed the microscope picture of 2 cells along the time series. As shown in FIGS. 1 to 6, particularly FIGS. 1 and 2, MDCK. Two cells began to swell after infection with the RS virus. After the sample is applied, some MDCK. Although 2 cells were killed, most MDCK. Two cells returned to normal.
  • Cell division started approximately 10 minutes after the sample was applied. Also, as shown in FIG. 5, when about 40 minutes had passed after the sample was applied, the expanded cells adhered to the bottom of the preparation, and the cell morphology returned to normal. The number of cells has not decreased. 10 minutes after the sample was applied, MDCK. Since the two cells start dividing and return to a normal form by 60 minutes, it is considered that the RS virus has been killed.
  • Example 7 (1) Test procedure The operator puts 4.5 ml of purified merinjo extract solution contained in three meringo extract tubes and purified vitamin E contained in one vitamin tube in a test tube. Dissolved in dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml.
  • This mixed liquid is a sample according to this example. Therefore, the components of the sample according to this example are as follows: gnetin C 1.37% by weight, resveratrol 0.44% by weight, dimethyl sulfoxide 60.46% by weight, vitamin E 2.22% by weight, moisture Is 35.51% by weight.
  • the other points are the same as in the sixth embodiment.
  • Example 8 (1) Test procedure The operator puts 4.5 ml of purified merinjo extract solution contained in three meringo extract tubes and purified vitamin E contained in one vitamin tube in a test tube. Dissolved in dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml.
  • Example 9 The worker dissolves the purified meringo extract solution contained in three meringo extract tubes and the purified vitamin E contained in one vitamin tube in 4.5 ml dimethyl sulfoxide stock solution in a test tube. I let you. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml.
  • Example 10 The worker dissolves the purified meringo extract solution contained in three meringo extract tubes and the purified vitamin E contained in one vitamin tube in 4.5 ml dimethyl sulfoxide stock solution in a test tube. I let you. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml.
  • Example 11 (1) Test Procedure (A) Preparation of Melinjo Extract Tube
  • the worker prepared a melinjo extract tube according to this example according to the following procedure. First, the worker dipped the Merinjo fruit in 55% by weight ethyl alcohol in a sealed bottle for 12 hours. The meringo was made by pulverizing the whole skin, fruit and seeds. The meringo was a raw meringo that was not dry. The mass of merinjo fruit for one meringo extract tube was 50 grams. The volume of ethyl alcohol for one meringo extract tube was 500 ml. While the meringo was soaked, the temperature of the ethyl alcohol was maintained at 90 degrees Celsius.
  • the ethyl alcohol continued to be stirred by the stirrer. After 12 hours of immersing the Merinjo in ethyl alcohol, the worker removed the Merinjo's solid components from the ethyl alcohol. Once the solid component was removed from the ethyl alcohol, the operator placed the ethyl alcohol in a sealed bottle. The operator caused the pump to discharge the gas in the bottle out of the bottle. At that time, the temperature inside the bottle was 40 degrees Celsius. As the gas was evacuated, the ethyl alcohol inside the bottle evaporated. The operator put 30 ml of the solid content remaining in the bottle into a predetermined tube. The tube containing this solid content is the melinjo extract tube in this example.
  • the components of the sample according to this example are as follows: gnetin C 1.37% by weight, resveratrol 0.44% by weight, dimethyl sulfoxide 60.46% by weight, vitamin E 2.22% by weight, moisture Is 35.51% by weight.
  • the phosphate buffered saline in which the bacterial colonies are dissolved is a bacterial sample according to this example.
  • the bacterial sample contained Staphylococcus aureus and Neisseria gonorrhoeae. These bacteria were sinking to the bottom of the preparation recess when one hour had passed since the sample according to this example was applied. All bacteria died 1 hour after the sample was applied.
  • Example 12 (1) Test procedure In this comparative example, the worker puts purified melinjo extract solution contained in nine meringo extract tubes and purified vitamin E contained in one vitamin tube in a test tube. In 13.5 milliliters of dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 18 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml.
  • This mixed liquid is a sample according to this example. Therefore, the components of the sample according to this example are 4.11% by weight of gnetin C, 1.33% by weight of resveratrol, 2.22% by weight of vitamin E, 58.17% by weight of dimethyl sulfoxide, and moisture. Is 34.17% by weight.
  • Other points in the sample preparation, the bacterial culture procedure, and the bacterial observation procedure are the same as in Example 11.
  • the volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml.
  • This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example were as follows: gnetin C 13.7% by weight, resveratrol 4.4% by weight, dimethyl sulfoxide 50.20% by weight, vitamin E 2.22% by weight, moisture Is 29.48% by weight. Other points are the same as in the first embodiment.
  • the components of the sample according to this comparative example are 1.37% by weight of gnetin C, 0.44% by weight of resveratrol, 61.86% by weight of dimethyl sulfoxide, and 36.33% by weight of water.
  • Other points are the same as in the first embodiment.
  • the components of the sample according to this comparative example are 2.22% by weight of vitamin E, 61.60% by weight of dimethyl sulfoxide, and 36.18% by weight of water. Other points are the same as in the first embodiment.
  • (2) Observation Result The observation result was the same as Comparative Example 2.
  • the volume of ethyl alcohol for one catechin extract tube was 500 ml.
  • the temperature of the ethyl alcohol was maintained at 90 degrees Celsius while the leaves were pickled.
  • the ethyl alcohol continued to be agitated by the stirrer while the leaf was pickled.
  • After 24 hours of chanoki leaves were soaked in ethyl alcohol, the worker extracted unpurified catechin extract from the ethyl alcohol supernatant.
  • a centrifugal evaporator (EC-57C manufactured by Sakuma Seisakusho Co., Ltd.) was used for extraction of the unpurified catechin extract.
  • the extraction time was 12 hours.
  • the unpurified catechin extract extracted by the centrifugal evaporator was a dry powder.
  • the worker added an aqueous dimethyl sulfoxide solution (the concentration of dimethyl sulfoxide was 63% by weight) to the crude catechin extract and stirred.
  • the amount of the aqueous dimethyl sulfoxide solution added was 3 ml with respect to 5 ml of the supernatant of ethyl alcohol from which the unpurified meringo extract was extracted.
  • the unpurified catechin extract in which a dimethyl sulfoxide aqueous solution is added and stirred is the unpurified catechin extract solution in this example.
  • the operator removed impurities from the unpurified catechin extract solution by using a centrifuge (Eppendorf Model 5415R).
  • the rotational speed of this centrifuge was 15400 rpm. This centrifuge was used for 10 minutes. By removing the impurities, the unpurified Kitekin extract solution became a purified catechin extract solution. The operator accommodated 2 grams (30 milliliters) of this purified catechin extract solution in a predetermined tube. This is a catechin extract tube.
  • This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example are catechin 16.80% by weight, vitamin E 2.22% by weight, dimethyl sulfoxide 51.02%, and moisture 29.96% by weight. Other points are the same as in the first embodiment.
  • the components of the sample according to this comparative example are 5.6% by weight of catechin, 2.22% by weight of vitamin E, 58.17% by weight of dimethyl sulfoxide, and 34.11% by weight of water. Other points are the same as in the first embodiment.
  • the volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml.
  • This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example were as follows: gnetin C 13.7% by weight, resveratrol 4.4% by weight, dimethyl sulfoxide 50.20% by weight, vitamin E 2.22% by weight, moisture Is 29.48% by weight.
  • the other points are the same as in the sixth embodiment.
  • MDCK Two cells began to swell after infection with the RS virus. MDCK. The cell division of the two cells stopped. After the sample is applied, MDCK. Two cells gradually decreased. MDCK. No cell division of 2 cells was observed.
  • the components of the sample according to this comparative example are 1.37% by weight of gnetin C, 0.44% by weight of resveratrol, 61.86% by weight of dimethyl sulfoxide, and 36.33% by weight of water.
  • MDCK Two cells began to swell after infection with the RS virus. MDCK. The cell division of the two cells stopped. After the sample was applied, a relatively large number of MDCK. 2 cells returned to normal, but some MDCK. 2-cell MDCK. Two cells remained expanded. MDCK. Two-cell cell division did not occur.
  • This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example are 5.6% by weight of catechin, 2.22% by weight of vitamin E, 58.07% by weight of dimethyl sulfoxide, and 34.11% by weight of water. The other points are the same as in the sixth embodiment.
  • This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example are catechin 16.80% by weight, vitamin E 2.22% by weight, dimethyl sulfoxide 51.02% by weight, and moisture 29.96% by weight. The other points are the same as in the sixth embodiment.
  • FIG. 7 shows MDCK. 2 When the cells were placed in the collagen gel coat preparation indentation, the MDCK. It is an optical micrograph of 2 cells.
  • FIG. 8 shows MDCK. 2 When 70 minutes have passed since the cells were placed in the preparation of the collagen gel coat preparation (when 10 minutes have passed since infection with the RS virus), the MDCK. It is an optical micrograph of 2 cells.
  • FIG. 9 shows MDCK. 2 When 120 minutes have passed since the cells were put into the preparation of the collagen gel coat preparation (60 minutes after infection with the RS virus), the MDCK. It is an optical micrograph of 2 cells.
  • FIG. 10 shows MDCK. 2 When the 180 cells have passed since the cells were placed in the preparation of the collagen gel coat preparation (120 minutes after infection with the RS virus), the MDCK.
  • FIG. 11 shows MDCK. It is the figure which showed the microscope picture of 2 cells along the time series. As shown in FIGS. 7 to 11, MDCK. Two cells began to swell after infection with the RS virus. MDCK. The cell division of the two cells stopped.
  • This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example are catechin 16.80% by weight, vitamin E 2.22% by weight, dimethyl sulfoxide 51.02% by weight, and moisture 29.96% by weight. Other points in the sample preparation, the bacterial culture procedure, and the bacterial observation procedure are the same as in Example 11.
  • This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example are 5.6% by weight of catechin, 2.22% by weight of vitamin E, 58.07% by weight of dimethyl sulfoxide, and 34.11% by weight of water. Other points in the sample preparation, the bacterial culture procedure, and the bacterial observation procedure are the same as in Example 11.
  • the components of the sample according to this comparative example are 2.22% by weight of vitamin E, 61.6% by weight of dimethyl sulfoxide, and 36.18% by weight of water.
  • Other points in the sample preparation, the bacterial culture procedure, and the bacterial observation procedure are the same as in Example 11.
  • the components of the sample according to this comparative example are 5.6% by weight of catechin, 58.07% by weight of dimethyl sulfoxide, 2.22% by weight of vitamin E, and 34.11% by weight of water.
  • Other points in the sample preparation, the bacterial culture procedure, and the bacterial observation procedure are the same as in Example 11.
  • Example 19 In this comparative example, the bacterial sample cultured in Example 11 was used. The operator applied only 20 microliters of phosphate buffered saline described in the description of Example 11 to the bacterial sample. Thereafter, the operator observed the bacterial sample. At 2 hours after the application of phosphate buffered saline, there was no change in the form or number of S. aureus.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Provided is an antibiotic capable of showing an immediate effect. The present invention relates to an antibiotic that comprises gnetin C, resveratrol, vitamin E and a fluidizing agent. The content by weight of gnetin C is 0.17-4.11 wt% inclusive. The content by weight of resveratrol is 0.06-1.33 wt% inclusive. The content by weight of vitamin E is 0.28-2.22 wt% inclusive. It is preferred that the content by weight of gnetin C is 0.17-1.37 wt% inclusive. In this case, it is preferred that the content by weight of resveratrol is 0.06-0.44 wt% inclusive. It is still preferred that the sum of the contents by weight of gnetin C and resveratrol is 0.23-1.81 wt% inclusive.

Description

抗生物質Antibiotics
 本発明は、抗生物質に関する。 The present invention relates to antibiotics.
 特許文献1は、インフルエンザウィルス感染予防剤を開示する。特許文献1に開示されたインフルエンザウィルス感染予防剤は、チャノキの葉を有効成分とする。特許文献1に開示されたインフルエンザウィルス感染予防剤は、抗原性に依存せずウィルスの感染を有効に防ぐことができ、かつ、人体に対して有害な副作用を持たない。 Patent Document 1 discloses an agent for preventing influenza virus infection. The preventive agent for influenza virus infection disclosed in Patent Document 1 uses tea leaves as an active ingredient. The influenza virus infection preventive agent disclosed in Patent Document 1 can effectively prevent virus infection without depending on antigenicity, and has no harmful side effects on the human body.
 特許文献2は、医薬組成物を開示する。特許文献2に開示された医薬組成物は修飾カテキンを含む。特許文献2に開示された医薬組成物は抗菌活性を上昇させることができる。 Patent Document 2 discloses a pharmaceutical composition. The pharmaceutical composition disclosed in Patent Document 2 contains a modified catechin. The pharmaceutical composition disclosed in Patent Document 2 can increase antibacterial activity.
特開平3-101623号公報Japanese Patent Laid-Open No. 3-101623 特表2007-521239号公報Special table 2007-521239 gazette
 しかしながら、特許文献1に開示されたインフルエンザウィルス感染予防剤と特許文献2に開示された医薬組成物には、その効果の発現が遅いという問題点がある。 However, the preventive agent for influenza virus infection disclosed in Patent Document 1 and the pharmaceutical composition disclosed in Patent Document 2 have a problem in that the onset of the effect is slow.
 本発明は、速く効果が現れる抗生物質の提供を目的とする。 The object of the present invention is to provide antibiotics that are effective quickly.
 本発明者は、上記課題を解決すべく鋭意研究した結果、メリンジョエキスとビタミンEとを含む抗生物質が細菌およびウィルスの活動を迅速に抑えることを見出し、本発明を完成させた。 As a result of earnest research to solve the above-mentioned problems, the present inventor has found that antibiotics containing melinjo extract and vitamin E can quickly suppress the activity of bacteria and viruses, and completed the present invention.
 すなわち、本発明は、抗生物質にかかる発明である。この抗生物質は、グネチンCと、レスベラトロールと、ビタミンEと、流動化物質とを含む。グネチンCの重量%が0.17重量%以上4.11重量%以下である。レスベラトロールの重量%が0.06重量%以上1.33重量%以下である。ビタミンEの重量%が0.28重量%以上2.22重量%以下である。 That is, the present invention relates to antibiotics. This antibiotic includes gnetin C, resveratrol, vitamin E, and a fluidizing substance. The weight% of gnetin C is 0.17 wt% or more and 4.11 wt% or less. The weight% of resveratrol is 0.06 wt% or more and 1.33 wt% or less. The weight% of vitamin E is 0.28 wt% or more and 2.22 wt% or less.
 また、上述したグネチンCの重量%が0.17重量%以上1.37重量%以下であることが好ましい。この場合、レスベラトロールの重量%が0.06重量%以上0.44重量%以下であることが好ましい。 Moreover, it is preferable that the weight% of the above-mentioned gnetin C is 0.17 wt% or more and 1.37 wt% or less. In this case, it is preferable that the weight% of resveratrol is 0.06 weight% or more and 0.44 weight% or less.
 もしくは、上述したグネチンCの重量%とレスベラトロールの重量%との和が0.23重量%以上1.81重量%以下であることが好ましい。 Or it is preferable that the sum of the weight% of the above-mentioned gnetin C and the weight% of resveratrol is 0.23% by weight or more and 1.81% by weight or less.
 また、上述したグネチンCの重量%が0.17重量%以上0.69重量%以下であることが好ましい。この場合、レスベラトロールの重量%が0.06重量%以上0.22重量%以下であることが好ましい。 Moreover, it is preferable that the weight% of the above-mentioned gnetin C is 0.17 wt% or more and 0.69 wt% or less. In this case, it is preferable that the weight% of resveratrol is 0.06 weight% or more and 0.22 weight% or less.
 本発明の抗生物質は、速く効果が現れる。 The antibiotic of the present invention is effective quickly.
実施例6にかかるMDCK.2細胞をコラーゲンゲルコートのプレパラートのくぼみに入れてから30分経過した時点のそのMDCK.2細胞の顕微鏡写真である。MDCK. 2 When the cells were placed in the collagen gel coat preparation indentation, the MDCK. It is a microscope picture of 2 cells. 実施例6にかかるMDCK.2細胞をコラーゲンゲルコートのプレパラートのくぼみに入れてから70分経過した時点のそのMDCK.2細胞の顕微鏡写真である。MDCK. 2 When the cells were put into the collagen gel coat preparation indentation, the MDCK. It is a microscope picture of 2 cells. 実施例6にかかるMDCK.2細胞をコラーゲンゲルコートのプレパラートのくぼみに入れてから100分経過した時点のそのMDCK.2細胞の顕微鏡写真である。MDCK. The MDCK.2 at 100 minutes after the 2 cells were placed in the preparation of the collagen gel coat preparation. It is a microscope picture of 2 cells. 実施例6にかかるMDCK.2細胞をコラーゲンゲルコートのプレパラートのくぼみに入れてから120分経過した時点のそのMDCK.2細胞の顕微鏡写真である。MDCK. 2 When the cells were placed in the collagen gel coat preparation indentation 120 minutes later, the MDCK. It is a microscope picture of 2 cells. 実施例6にかかるMDCK.2細胞をコラーゲンゲルコートのプレパラートのくぼみに入れてから150分経過した時点のそのMDCK.2細胞の顕微鏡写真である。MDCK. 2 When the cells were placed in the collagen gel coat preparation indentation 150 minutes later, their MDCK. It is a microscope picture of 2 cells. 実施例6にかかるMDCK.2細胞の顕微鏡写真を時系列に沿って示した図である。MDCK. It is the figure which showed the microscope picture of 2 cells along the time series. 比較例14にかかるMDCK.2細胞をコラーゲンゲルコートのプレパラートのくぼみに入れてから30分経過した時点のそのMDCK.2細胞の顕微鏡写真である。MDCK. 2 When the cells were placed in the collagen gel coat preparation indentation, the MDCK. It is a microscope picture of 2 cells. 比較例14にかかるMDCK.2細胞をコラーゲンゲルコートのプレパラートのくぼみに入れてから70分経過した時点のそのMDCK.2細胞の顕微鏡写真である。MDCK. 2 When the cells were put into the collagen gel coat preparation indentation, the MDCK. It is a microscope picture of 2 cells. 比較例14にかかるMDCK.2細胞をコラーゲンゲルコートのプレパラートのくぼみに入れてから120分経過した時点のそのMDCK.2細胞の顕微鏡写真である。MDCK. 2 When the cells were placed in the collagen gel coat preparation indentation 120 minutes later, the MDCK. It is a microscope picture of 2 cells. 比較例14にかかるMDCK.2細胞をコラーゲンゲルコートのプレパラートのくぼみに入れてから180分経過した時点のそのMDCK.2細胞の顕微鏡写真である。MDCK. 2 MDCK. Of the cells at the time when 180 minutes have passed since the cells were put into the preparation of the collagen gel coat preparation. It is a microscope picture of 2 cells. 比較例14にかかるMDCK.2細胞の顕微鏡写真を時系列に沿って示した図である。MDCK. It is the figure which showed the microscope picture of 2 cells along the time series.
[成分の説明]
 本発明について以下詳細に説明する。本発明の抗生物質は、グネチンCと、レスベラトロールと、ビタミンEと、流動化物質とを含む。
[Description of ingredients]
The present invention will be described in detail below. Antibiotics of the present invention include gnetin C, resveratrol, vitamin E, and a fluidizing substance.
(グネチンCの説明)
 グネチンCは、レスベラトロールの二量体である。グネチンCの構造式は周知なのでここでは繰り返されない。グネチンCは、例えばメリンジョ(学名:Gnetum gnemon)の果実に含まれる。本発明においては、グネチンCの重量%は0.17重量%以上4.11重量%以下である。好ましくは、グネチンCの重量%は0.17重量%以上1.37重量%以下である。より好ましくは、グネチンCの重量%は0.17重量%以上0.69重量%以下である。
(Description of Gunnetin C)
Gnetin C is a dimer of resveratrol. The structural formula of gnetin C is well known and will not be repeated here. Gnetin C is contained, for example, in the fruit of Merinjo (scientific name: Gnetum gnemon). In the present invention, the weight% of gnetin C is 0.17 wt% or more and 4.11 wt% or less. Preferably, the weight% of gnetin C is 0.17 wt% or more and 1.37 wt% or less. More preferably, the weight% of gnetin C is 0.17 wt% or more and 0.69 wt% or less.
(レスベラトロールの説明)
 レスベラトロールはスチルベン誘導体の一種である。レスベラトロールの構造式は周知なのでここでは繰り返されない。レスベラトロールは、赤ワイン、赤ブドウの果皮、ピーナッツの皮、イタドリ、メリンジョなどに含まれる。本発明においては、レスベラトロールの重量%は0.06重量%以上1.33重量%以下である。好ましくは、レスベラトロールの重量%は0.06重量%以上0.44重量%以下である。より好ましくは、レスベラトロールの重量%は0.06重量%以上0.22重量%以下である。
(Description of resveratrol)
Resveratrol is a kind of stilbene derivative. The structural formula of resveratrol is well known and will not be repeated here. Resveratrol is found in red wine, red grape skin, peanut skin, itadori, melinjo and others. In the present invention, the weight percent of resveratrol is 0.06 wt% or more and 1.33 wt% or less. Preferably, the weight percent of resveratrol is 0.06 wt% or more and 0.44 wt% or less. More preferably, the weight percent of resveratrol is 0.06 wt% or more and 0.22 wt% or less.
 なお、グネチンCの重量%が0.17重量%以上1.37重量%以下であり、かつ、レスベラトロールの重量%が0.06重量%以上0.44重量%以下であるとき、グネチンCの重量%とレスベラトロールの重量%との和が0.23重量%以上1.81重量%以下であることが好ましい。 It should be noted that when the weight% of gnetin C is 0.17 wt% or more and 1.37 wt% or less and the weight% of resveratrol is 0.06 wt% or more and 0.44 wt% or less, It is preferable that the sum of the weight percent of the above and the weight percent of resveratrol is 0.23% by weight or more and 1.81% by weight or less.
(ビタミンEの説明)
 ビタミンEの構造は周知なのでここではその説明が繰り返されない。本発明においては、ビタミンEの重量%は0.28重量%以上2.22重量%以下である。好ましくは、ビタミンEの重量%は0.28重量%以上1.11重量%以下である。
(Explanation of vitamin E)
Since the structure of vitamin E is well known, its description is not repeated here. In the present invention, the vitamin E weight percent is 0.28 wt% or more and 2.22 wt% or less. Preferably, the vitamin E weight percent is 0.28 wt% or more and 1.11 wt% or less.
(流動化物質の説明)
 流動化物質は、本発明の抗生物質を流動しやすくする物質である。流動化物質の具体的な成分は、グネチンC、レスベラトロール、および、ビタミンEの相乗効果を完全に失わせるものでない限り、特に限定されない。ただし、流動化物質は、グネチンC、レスベラトロール、および、ビタミンEの相乗効果を損なわない物質であることが好ましい。流動化物質は、グネチンC、レスベラトロール、および、ビタミンEの相乗効果を高める物質であることがより好ましい。流動化物質の例には、ジメチルスルホキシド、精製水がある。
(Description of fluidized material)
The fluidizing substance is a substance that facilitates the flow of the antibiotic of the present invention. The specific components of the fluidizing substance are not particularly limited as long as the synergistic effects of gnetin C, resveratrol, and vitamin E are not completely lost. However, the fluidizing substance is preferably a substance that does not impair the synergistic effect of gnetin C, resveratrol, and vitamin E. The fluidizing substance is more preferably a substance that enhances the synergistic effect of gnetin C, resveratrol, and vitamin E. Examples of fluidizing materials include dimethyl sulfoxide and purified water.
(その他の成分の説明)
 本発明の抗生物質は、グネチンC、レスベラトロール、ビタミンE、および、流動化物質以外の成分を含んでもよい。そのような成分の例には、グネチンCの配糖体がある。グネチンCの配糖体の例には、グネモノシドAと、グネモノシドCと、グネモノシドDとがある。そのような成分の具体的な内容は、グネチンC、レスベラトロール、および、ビタミンEの相乗効果を完全に失わせるものでない限り、特に限定されない。もちろん、本発明の抗生物質は、グネチンC、レスベラトロール、ビタミンE、および、流動化物質のみからなっていてもよい。
(Description of other ingredients)
Antibiotics of the present invention may contain components other than gnetin C, resveratrol, vitamin E, and fluidizing substances. An example of such a component is Gnetin C glycoside. Examples of glycosides of gnetin C include gunemonoside A, gunemonoside C, and gunemonoside D. The specific content of such components is not particularly limited as long as the synergistic effect of gnetin C, resveratrol, and vitamin E is not completely lost. Of course, the antibiotic of the present invention may consist only of gnetin C, resveratrol, vitamin E, and a fluidizing substance.
[製造方法の説明]
 本発明の抗生物質の製造方法は特に限定されない。その一例は、エキス抽出工程と、果実粉砕工程と、ビタミンE添加工程と、流動化工程とを備える。エキス抽出工程は、メリンジョの果実からメリンジョエキスを抽出する工程である。メリンジョエキスは、メリンジョの果実のエキスである。メリンジョエキスがグネチンCとレスベラトロールとを含む。果実粉砕工程は、メリンジョの果実を粉砕する工程である。メリンジョの果実が粉砕されるのは、エキス抽出工程においてメリンジョの果実からメリンジョエキスが抽出される前である。ビタミンE添加工程は、エキス抽出工程の後にメリンジョエキスにビタミンEを添加する工程である。流動化工程は、メリンジョエキスに流動性を付与する工程である。
[Description of manufacturing method]
The method for producing the antibiotic of the present invention is not particularly limited. One example includes an extract extraction process, a fruit crushing process, a vitamin E addition process, and a fluidization process. The extract extraction step is a step of extracting the meringo extract from the fruit of meringo. Melinjo extract is an extract of the fruit of Merinjo. Melinjo extract contains gnetin C and resveratrol. The fruit crushing step is a step of crushing the fruit of Merinjo. Merinjo fruit is pulverized before the meringo extract is extracted from merinjo fruit in the extract extraction process. The vitamin E addition step is a step of adding vitamin E to the meringo extract after the extract extraction step. The fluidizing step is a step of imparting fluidity to the meringo extract.
[用途及び使用方法の説明]
 本発明にかかる抗生物質は、次に述べられる様々な用途に利用できる。その用途は、細菌およびウィルスの駆除、それらの殺菌、ならびに、それらの増殖抑制である。本発明にかかる抗生物質が対象とする細菌およびウィルスの範囲は特に限定されない。本発明にかかる抗生物質は、様々な細菌および様々なウィルスを駆除できる。本発明にかかる抗生物質は、様々な方法で使用できる。その例には、内服薬、塗り薬、湿布、および、スプレーがある。
[Description of usage and usage]
The antibiotic according to the present invention can be used for various applications described below. Its uses are the control of bacteria and viruses, their disinfection, and their growth inhibition. The range of bacteria and viruses targeted by the antibiotic according to the present invention is not particularly limited. Antibiotics according to the present invention can combat various bacteria and various viruses. The antibiotic according to the present invention can be used in various ways. Examples include internal medicines, paints, poultices, and sprays.
 以下に、実施例を示して本発明を具体的に説明する。ただし、本発明はこれらに限定されない。 Hereinafter, the present invention will be specifically described with reference to examples. However, the present invention is not limited to these.
[実施例1]
 (1) 試験手順
 (A) メリンジョエキスチューブの調製
 作業者は、メリンジョエキスチューブを調製した。「メリンジョエキスチューブ」とは、後述される精製メリンジョエキス溶液が後述される所定のチューブに収容されたものである。作業者は、以下の手順に従って本実施例にかかるメリンジョエキスチューブを調製した。まず、作業者は、メリンジョ(学名:Gnetum gnemon)の果実を摂氏110度で10分間焙煎した。メリンジョエキスチューブ1本分のメリンジョの果実の質量は50グラムであった。焙煎により、そのメリンジョの含水率は8重量%となった。そのメリンジョは、果皮と果実と種子とが丸ごと粉砕されたものであった。焙煎が終了すると、作業者は、焙煎されたメリンジョを密封されたビンの中で55重量%のエチルアルコールに24時間漬けた。メリンジョエキスチューブ1本分のエチルアルコールの体積は500ミリリットルであった。そのメリンジョが漬けられている間、そのエチルアルコールの温度は摂氏90度に維持された。そのメリンジョが漬けられている間、そのエチルアルコールはスターラによって撹拌され続けられていた。24時間メリンジョがエチルアルコールに漬けられた後、作業者は、そのエチルアルコールの上澄から未精製メリンジョエキスを抽出した。未精製メリンジョエキスの抽出には遠心エバポレータ(株式会社佐久間製作所製EC-57C)が用いられた。抽出時間は12時間であった。遠心エバポレータによって抽出された未精製メリンジョエキスは乾燥した粉末状であった。未精製メリンジョエキスが抽出されると、作業者は、その未精製メリンジョエキスにジメチルスルホキシド水溶液(ジメチルスルホキシドの濃度は63重量%)を加え撹拌した。ジメチルスルホキシド水溶液の添加量は、未精製メリンジョエキスが抽出されたエチルアルコールの上澄5ミリリットルに対し、3ミリリットルであった。ジメチルスルホキシド水溶液が加えられ撹拌された未精製メリンジョエキスが、本実施例における未精製メリンジョエキス溶液である。撹拌が終了すると、作業者は、遠心分離機(Eppendorf社 Model 5415R)を用いることにより、その未精製メリンジョエキス溶液から不純物を除去した。この遠心分離機の回転速度は15400rpmであった。この遠心分離機の使用時間は10分間であった。不純物が除去されたことにより、未精製メリンジョエキス溶液は精製メリンジョエキス溶液となった。作業者は、この精製メリンジョエキス溶液2グラム(30ミリリットル)を所定のチューブに収容した。これが、メリンジョエキスチューブである。1本のメリンジョエキスチューブに入っている精製メリンジョエキス溶液の成分は、グネチンCが0.46重量%、レスベラトロールが0.15重量%、ジメチルスルホキシドが62.62重量%、水分が36.77重量%である。
[Example 1]
(1) Test Procedure (A) Preparation of Melinjo Extract Tube The worker prepared a Melinjo extract tube. The “merinjo extract tube” is a tube in which a purified merinjo extract solution described later is contained in a predetermined tube described later. The operator prepared the meringo extract tube according to this example according to the following procedure. First, the worker roasted the fruit of Melinjo (scientific name: Gnetum gnemon) at 110 degrees Celsius for 10 minutes. The mass of merinjo fruit for one meringo extract tube was 50 grams. By roasting, the water content of the melinjo was 8% by weight. The meringo was made by pulverizing the whole skin, fruit and seeds. When the roasting was finished, the operator soaked the roasted melinjo in 55% by weight ethyl alcohol in a sealed bottle for 24 hours. The volume of ethyl alcohol for one meringo extract tube was 500 ml. While the meringo was soaked, the temperature of the ethyl alcohol was maintained at 90 degrees Celsius. While the meringo was soaked, the ethyl alcohol continued to be stirred by the stirrer. After the meringo was soaked in ethyl alcohol for 24 hours, the worker extracted an unpurified meringo extract from the ethyl alcohol supernatant. A centrifugal evaporator (EC-57C manufactured by Sakuma Seisakusho Co., Ltd.) was used for extraction of the unpurified melinjo extract. The extraction time was 12 hours. The unpurified meringo extract extracted by the centrifugal evaporator was in the form of a dry powder. When the unpurified melinjo extract was extracted, the worker added an aqueous dimethyl sulfoxide solution (the concentration of dimethyl sulfoxide was 63% by weight) to the unpurified melinjo extract and stirred. The amount of the aqueous dimethyl sulfoxide solution added was 3 ml with respect to 5 ml of the supernatant of ethyl alcohol from which the unpurified meringo extract was extracted. The unpurified meringo extract to which the aqueous dimethyl sulfoxide solution has been added and stirred is the unpurified meringo extract solution in this example. When the stirring was completed, the operator removed impurities from the unpurified melinjo extract solution by using a centrifuge (Eppendorf Model 5415R). The rotational speed of this centrifuge was 15400 rpm. This centrifuge was used for 10 minutes. By removing the impurities, the unpurified meringo extract solution became a purified meringo extract solution. The operator accommodated 2 grams (30 milliliters) of this purified meringo extract solution in a predetermined tube. This is a meringo extract tube. The purified meringo extract solution contained in one meringo extract tube is composed of 0.46% by weight of gnetin C, 0.15% by weight of resveratrol, 62.62% by weight of dimethyl sulfoxide, and water content. 36.77% by weight.
 (B) ビタミンチューブの調製
 作業者は、ビタミンE (山口化研株式会社製)の粉末50グラムをビンに入れた。次に、作業者は、そのビンにエチルアルコール(濃度は55%重量)500ミリリットルを入れた。これにより、ビタミンEの粉末はそのエチルアルコールに漬けられたこととなる。その粉末はそのビンに密封された状態のままそのエチルアルコールに12時間漬けられた。その間、エチルアルコールの温度は摂氏80~摂氏90度であった。その間、その粉末とそのエチルアルコールとはスターラで攪拌された。その後、作業者は、その混合物を12時間放置した。12時間経過後、その混合物表面に薄い油膜が形成された。その油膜が精製されたビタミンE(以下「精製ビタミンE」と称される)である。作業者は、この精製ビタミンE10ミリグラム(20ミリリットル)を所定のチューブに収容した。このチューブは、メリンジョエキスチューブの調製に用いられるものと同じ種類のチューブである。精製ビタミンE10ミリグラムが収容されたそのチューブが、ビタミンチューブである。
(B) Preparation of vitamin tube The operator put 50 grams of vitamin E powder (manufactured by Yamaguchi Kaken Co., Ltd.) into a bottle. The worker then placed 500 ml of ethyl alcohol (concentration 55% weight) in the bottle. Thereby, the powder of vitamin E is immersed in the ethyl alcohol. The powder was immersed in the ethyl alcohol for 12 hours while sealed in the bottle. Meanwhile, the temperature of ethyl alcohol was 80 to 90 degrees Celsius. Meanwhile, the powder and the ethyl alcohol were stirred with a stirrer. Thereafter, the worker left the mixture for 12 hours. After 12 hours, a thin oil film was formed on the surface of the mixture. The oil film is purified vitamin E (hereinafter referred to as “purified vitamin E”). The worker accommodated 10 milligrams (20 milliliters) of this purified vitamin E in a predetermined tube. This tube is the same type of tube used for the preparation of melinjo extract tubes. The tube containing 10 milligrams of purified vitamin E is a vitamin tube.
 (B) 試料の調製
 作業者は、3本のメリンジョエキスチューブに収容されていた精製メリンジョエキス溶液(質量は6グラム)と1本のビタミンチューブに収容されていた精製ビタミンE(10ミリグラム)とを試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。この混合液が、本実施例にかかる試料である。したがって、本実施例にかかる試料の成分は、グネチンCが1.37重量%、レスベラトロールが0.44重量%、ジメチルスルホキシドが60.46重量%、ビタミンEが2.22重量%、水分が35.51重量%である。
(B) Preparation of sample The worker prepared purified melinjo extract solution (mass was 6 grams) contained in three meringo extract tubes and purified vitamin E (10 milligrams) contained in one vitamin tube. Were dissolved in 4.5 ml of dimethyl sulfoxide stock solution in a test tube. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. This mixed liquid is a sample according to this example. Therefore, the components of the sample according to this example are as follows: gnetin C 1.37% by weight, resveratrol 0.44% by weight, dimethyl sulfoxide 60.46% by weight, vitamin E 2.22% by weight, moisture Is 35.51% by weight.
 (C) 液体培地の調製
 まず、作業者は、1リットルの滅菌精製水(アズワン株式会社製)に次の7種類の物質を加えた。1つ目の物質は、10グラムの粉末培地(和光純薬工業株式会社製,E-MEM Powder,品番054-09001)である。2つ目の物質は、生後10日以内の新生児仔牛の血清 (コスモ・バイオ株式会社製,品番04-102-1A)である。作業者は、この血清を100ミリリットル前述された滅菌精製水に加えた。3つ目の物質はペニシリン・ストレプトマイシン(和光純薬工業株式会社製,品番168-23191)である。このペニシリン・ストレプトマイシンの添加量は10ミリリットルであった。4つ目の物質は、ビタミン液(和光純薬工業株式会社製,MEMビタミン溶液,品番130-17141)である。このビタミン液の添加量は10ミリリットルであった。5つ目の物質は、非必須アミノ酸液(和光純薬工業株式会社製,MEM非必須アミノ酸溶液,品番139-15651)である。この非必須アミノ酸液の添加量は10ミリリットルであった。6つ目の物質は、ピルビン酸ナトリウム溶液(和光純薬工業株式会社製,ピルビン酸ナトリウム溶液,品番190-14881)である。このピルビン酸ナトリウム溶液の添加量は10ミリリットルであった。7つ目の物質は、13.4グラムの炭酸水素ナトリウム(和光純薬工業株式会社製,品番198-01315)である。これら7種類の物質が前述された滅菌精製水に加えられると、作業者は、それらの物質が加えられた滅菌精製水を撹拌した。撹拌された滅菌精製水が本実施例にかかる液体培地である。以下の説明では、この液体培地を「液培地」と称する。
(C) Preparation of liquid medium First, the operator added the following seven kinds of substances to 1 liter of sterilized purified water (manufactured by ASONE CORPORATION). The first substance is 10 grams of powder medium (Wako Pure Chemical Industries, E-MEM Powder, product number 054-09001). The second substance is the serum of a newborn calf within 10 days after birth (product number 04-102-1A, manufactured by Cosmo Bio Inc.). The operator added 100 ml of this serum to the sterile purified water described above. The third substance is penicillin streptomycin (manufactured by Wako Pure Chemical Industries, Ltd., product number 168-23191). The amount of penicillin / streptomycin added was 10 ml. The fourth substance is a vitamin solution (Wako Pure Chemical Industries, Ltd., MEM vitamin solution, product number 130-17141). The amount of vitamin solution added was 10 ml. The fifth substance is a non-essential amino acid solution (Wako Pure Chemical Industries, Ltd., MEM non-essential amino acid solution, product number 139-15651). The amount of the non-essential amino acid solution added was 10 ml. The sixth substance is a sodium pyruvate solution (manufactured by Wako Pure Chemical Industries, Ltd., sodium pyruvate solution, product number 190-14881). The amount of this sodium pyruvate solution added was 10 ml. The seventh substance is 13.4 grams of sodium bicarbonate (Wako Pure Chemical Industries, Ltd., product number 198-01315). When these seven substances were added to the sterilized purified water described above, the operator agitated the sterilized purified water with the substances added. Stirred sterilized purified water is the liquid medium according to this example. In the following description, this liquid medium is referred to as “liquid medium”.
 (D) コラーゲンゲルコートのプレパラート作製
 まず、作業者は、くぼみのあるプレパラートに、50マイクロリットルのコラーゲン培地(株式会社ニッピ製,コラーゲンゲル細胞培養キット,品番891503)を塗り広げた。コラーゲン培地が塗り広げられると、作業者は、そのプレパラートをインキュベータに収容した。インキュベータの内部の気温は摂氏37度であった。インキュベータ内部で、そのプレパラートには波長365ナノメートルの紫外線が照射されていた。これにより、その培地は乾燥した。紫外線が2時間照射されると、作業者はそのプレパラートをインキュベータから取り出した。これが、細胞の観察に用いられるコラーゲンゲルコートのプレパラートである。
(D) Preparation of Collagen Gel Coat Preparation First, an operator spread 50 microliters of collagen medium (manufactured by Nippi Co., Ltd., collagen gel cell culture kit, product number 891503) on the prepared preparation. Once the collagen medium was spread, the operator placed the preparation in an incubator. The temperature inside the incubator was 37 degrees Celsius. Inside the incubator, the preparation was irradiated with ultraviolet rays having a wavelength of 365 nm. Thereby, the culture medium was dried. When the ultraviolet rays were irradiated for 2 hours, the worker removed the preparation from the incubator. This is a collagen gel coat preparation used for cell observation.
 (E) 細胞の観察
 まず、作業者は、コラーゲンゲルコートのプレパラートのくぼみに20マイクロリットルの液培地で培養されているMDCK.2細胞(ATCC番号CRL-2936)をその液培地ごと入れた。MDCK.2細胞がそのプレパラートに入れられてから60分が経過した後、作業者は、そのMDCK.2細胞に次に述べられる液体20マイクロリットルをかけた。その液体はインフルエンザウィルスであるH3N2(ATCC番号VR-1680)を含んでいた。これにより、そのMDCK.2細胞はH3N2に感染した。感染から50分が経過した後、作業者は、H3N2に感染したMDCK.2細胞へ本実施例にかかる試料20マイクロリットルをかけた。これらの作業は、光学顕微鏡で観察可能な環境で実施された。これらの作業が完了した後、作業者は、引続きMDCK.2細胞を光学顕微鏡で観察した。
(E) Observation of cells First, the operator was cultivated in 20 microliters of liquid medium in a preparation of collagen gel-coated preparation. Two cells (ATCC number CRL-2936) were added together with the liquid medium. MDCK. After 60 minutes have passed since the two cells were placed in the preparation, the operator can then confirm the MDCK. Two cells were loaded with 20 microliters of the liquid described below. The liquid contained the influenza virus H3N2 (ATCC number VR-1680). As a result, the MDCK. Two cells were infected with H3N2. After 50 minutes had passed since the infection, the worker had MDCK. A sample of 20 microliters according to this example was applied to 2 cells. These operations were performed in an environment that can be observed with an optical microscope. After these operations are completed, the worker continues to use MDCK. Two cells were observed with a light microscope.
 (2) 観察結果
 MDCK.2細胞は、H3N2に感染した後、膨張し始めた。試料がかけられてから10分後、一部のMDCK.2細胞が死滅したものの、大部分のMDCK.2細胞はプレパラート底面に接着し正常な形態に戻り始めた。試料がかけられてから約50分後にはMDCK.2細胞の細胞分裂が開始された。試料がかけられてから50分後にMDCK.2細胞が正常に戻り分裂を開始することから、H3N2が死滅したものと考えられる。
(2) Observation results MDCK. Two cells began to swell after infection with H3N2. Ten minutes after the sample was applied, some MDCK. Although 2 cells were killed, most MDCK. 2 cells began to adhere to the bottom of the preparation and return to normal morphology. About 50 minutes after the sample was applied, MDCK. Two cell divisions were initiated. 50 minutes after the sample was applied, MDCK. Since 2 cells returned to normal and started dividing, it is considered that H3N2 was killed.
[実施例2]
 (1) 試験手順
 作業者は、9本のメリンジョエキスチューブに収容されていた精製メリンジョエキス溶液と1本のビタミンチューブに収容されていた精製ビタミンEとを試験管内で13.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は18ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。この混合液が、本実施例にかかる試料である。したがって、本実施例にかかる試料の成分は、グネチンCが4.11重量%、レスベラトロールが1.33重量%、ジメチルスルホキシドが58.17重量%、ビタミンEが2.22重量%、水分が34.17重量%である。その他の点は実施例1と同様である。
[Example 2]
(1) Test procedure An operator shall prepare 13.5 ml of purified meringo extract solution contained in nine meringo extract tubes and purified vitamin E contained in one vitamin tube in a test tube. Dissolved in dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 18 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. This mixed liquid is a sample according to this example. Therefore, the components of the sample according to this example are 4.11% by weight of gnetin C, 1.33% by weight of resveratrol, 58.17% by weight of dimethyl sulfoxide, 2.22% by weight of vitamin E, moisture Is 34.17% by weight. Other points are the same as in the first embodiment.
 (2) 観察結果
 MDCK.2細胞は、H3N2に感染した後、膨張し始めた。試料がかけられた後、ほぼすべてのMDCK.2細胞は正常に戻った。試料がかけられてから約50分後に細胞分裂が開始された。
(2) Observation results MDCK. Two cells began to swell after infection with H3N2. After the sample has been applied, almost all MDCK. Two cells returned to normal. Cell division started approximately 50 minutes after the sample was applied.
[実施例3]
 (1) 試験手順
 作業者は、3本のメリンジョエキスチューブに収容されていた精製メリンジョエキス溶液と1本のビタミンチューブに収容されていた精製ビタミンEとを試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。次に、作業者は、その混合液にジメチルスルホキシド水溶液(ジメチルスルホキシドの濃度は63重量%)を加えた。これにより、その混合液の体積は2倍となった。グネチンCの濃度とレスベラトロールの濃度とビタミンEの濃度とは2分の1に希釈された。この混合液が、本実施例にかかる試料である。したがって、本実施例にかかる試料の成分は、グネチンCが0.69重量%、レスベラトロールが0.22重量%、ジメチルスルホキシドが61.72重量%、ビタミンEが1.11重量%、水分が36.26重量%である。その他の点は実施例1と同様である。
[Example 3]
(1) Test procedure The operator puts 4.5 ml of purified merinjo extract solution contained in three meringo extract tubes and purified vitamin E contained in one vitamin tube in a test tube. Dissolved in dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. Next, the worker added a dimethyl sulfoxide aqueous solution (the concentration of dimethyl sulfoxide was 63% by weight) to the mixed solution. Thereby, the volume of the liquid mixture was doubled. The concentrations of gnetin C, resveratrol, and vitamin E were diluted by half. This mixed liquid is a sample according to this example. Therefore, the components of the sample according to this example are as follows: gnetin C is 0.69% by weight, resveratrol is 0.22% by weight, dimethyl sulfoxide is 61.72% by weight, vitamin E is 1.11% by weight, moisture Is 36.26% by weight. Other points are the same as in the first embodiment.
 (2) 観察結果
 観察結果は実施例2と同様であった。
(2) Observation result The observation result was the same as that of Example 2.
[実施例4]
 (1) 試験手順
 作業者は、3本のメリンジョエキスチューブに収容されていた精製メリンジョエキス溶液と1本のビタミンチューブに収容されていた精製ビタミンEとを試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。次に、作業者は、その混合液にジメチルスルホキシド水溶液(ジメチルスルホキシドの濃度は63重量%)を加えた。これにより、その混合液の体積は4倍となった。グネチンCの濃度とレスベラトロールの濃度とビタミンEの濃度とは4分の1に希釈された 。この混合液が、本実施例にかかる試料である。したがって、本実施例にかかる試料の成分は、グネチンCが0.34重量%、レスベラトロールが0.11重量%、ジメチルスルホキシドが62.36重量%、ビタミンEが0.56重量%、水分が36.63重量%である。その他の点は実施例1と同様である。
[Example 4]
(1) Test procedure The operator puts 4.5 ml of purified merinjo extract solution contained in three meringo extract tubes and purified vitamin E contained in one vitamin tube in a test tube. Dissolved in dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. Next, the worker added a dimethyl sulfoxide aqueous solution (the concentration of dimethyl sulfoxide was 63% by weight) to the mixed solution. Thereby, the volume of the liquid mixture became 4 times. The concentrations of gnetin C, resveratrol, and vitamin E were diluted by a factor of four. This mixed liquid is a sample according to this example. Therefore, the components of the sample according to the present example were 0.34% by weight of gnetin C, 0.11% by weight of resveratrol, 62.36% by weight of dimethyl sulfoxide, 0.56% by weight of vitamin E, moisture Is 36.63 wt%. Other points are the same as in the first embodiment.
 (2) 観察結果
 観察結果は実施例2と同様であった。
(2) Observation result The observation result was the same as that of Example 2.
[実施例5]
 (1) 試験手順
 作業者は、3本のメリンジョエキスチューブに収容されていた精製メリンジョエキス溶液と1本のビタミンチューブに収容されていた精製ビタミンEとを試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。次に、作業者は、その混合液にジメチルスルホキシド水溶液(ジメチルスルホキシドの濃度は63重量%)を加えた。これにより、その混合液の体積は8倍となった。グネチンCの濃度とレスベラトロールの濃度とビタミンEの濃度とは8分の1に希釈された 。この混合液が、本実施例にかかる試料である。したがって、本実施例にかかる試料の成分は、グネチンCが0.17重量%、レスベラトロールが0.06重量%、ジメチルスルホキシドが62.68重量%、ビタミンEが0.28重量%、水分が36.81重量%である。その他の点は実施例1と同様である。
[Example 5]
(1) Test procedure The operator puts 4.5 ml of purified merinjo extract solution contained in three meringo extract tubes and purified vitamin E contained in one vitamin tube in a test tube. Dissolved in dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. Next, the worker added a dimethyl sulfoxide aqueous solution (the concentration of dimethyl sulfoxide was 63% by weight) to the mixed solution. Thereby, the volume of the liquid mixture became 8 times. The concentrations of gnetin C, resveratrol, and vitamin E were diluted 1/8. This mixed liquid is a sample according to this example. Therefore, the components of the sample according to this example are 0.17% by weight of gnetin C, 0.06% by weight of resveratrol, 62.68% by weight of dimethyl sulfoxide, 0.28% by weight of vitamin E, moisture Is 36.81% by weight. Other points are the same as in the first embodiment.
 (2) 観察結果
 観察結果は実施例2と同様であった。
(2) Observation result The observation result was the same as that of Example 2.
[実施例6]
 (1) 試験手順
 作業者は、試料の調製にあたり、メリンジョエキスチューブ9本(精製メリンジョエキス溶液18グラム)と1本のビタミンチューブに収容されていた精製ビタミンE(10ミリグラム)とを試験管内で13.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は18ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。この混合液が、本実施例にかかる試料である。したがって、本実施例にかかる試料の成分は、グネチンCが4.11重量%、レスベラトロールが1.33重量%、ジメチルスルホキシドが58.17重量%、ビタミンEが2.22重量%、水分が34.17重量%である。また、作業者は、細胞の観察にあたり、コラーゲンゲルコートのプレパラートのくぼみにMDCK.2細胞を入れた。このMDCK.2細胞は20マイクロリットルの液培地で培養されていた。このMDCK.2細胞はその液培地ごとそのくぼみに入れられた。MDCK.2細胞がそのプレパラートに入れられてから60分が経過した後、作業者は、そのMDCK.2細胞に次に述べられる液体20マイクロリットルをかけた。その液体はRSウィルス(ATCC番号VR-1580)を含んでいた。これにより、そのMDCK.2細胞はRSウィルスに感染した。その他の点は実施例1と同様である。
[Example 6]
(1) Test procedure In preparation of the sample, the operator tested nine meringo extract tubes (18 grams of purified meringo extract solution) and purified vitamin E (10 milligrams) contained in one vitamin tube. It was dissolved in 13.5 ml dimethyl sulfoxide stock solution in a tube. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 18 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. This mixed liquid is a sample according to this example. Therefore, the components of the sample according to this example are 4.11% by weight of gnetin C, 1.33% by weight of resveratrol, 58.17% by weight of dimethyl sulfoxide, 2.22% by weight of vitamin E, moisture Is 34.17% by weight. In addition, when observing the cells, the operator placed MDCK. Two cells were added. This MDCK. Two cells were cultured in 20 microliters of liquid medium. This MDCK. Two cells were placed in the wells along with the liquid medium. MDCK. After 60 minutes have passed since the two cells were placed in the preparation, the operator can then confirm the MDCK. Two cells were loaded with 20 microliters of the liquid described below. The liquid contained RS virus (ATCC number VR-1580). As a result, the MDCK. Two cells were infected with RS virus. Other points are the same as in the first embodiment.
 (2) 観察結果
 図1は本実施例にかかるMDCK.2細胞をコラーゲンゲルコートのプレパラートのくぼみに入れてから30分経過した時点のそのMDCK.2細胞の光学顕微鏡写真である。図2は本実施例にかかるMDCK.2細胞をコラーゲンゲルコートのプレパラートのくぼみに入れてから70分経過した時点(RSウィルスに感染してから10分経過した時点)のそのMDCK.2細胞の光学顕微鏡写真である。図3は本実施例にかかるMDCK.2細胞をコラーゲンゲルコートのプレパラートのくぼみに入れてから100分経過した時点(RSウィルスに感染してから40分経過した時点)のそのMDCK.2細胞の光学顕微鏡写真である。図4は本実施例にかかるMDCK.2細胞をコラーゲンゲルコートのプレパラートのくぼみに入れてから120分経過した時点(RSウィルスに感染してから60分経過した時点)のそのMDCK.2細胞の光学顕微鏡写真である。図5は本実施例にかかるMDCK.2細胞をコラーゲンゲルコートのプレパラートのくぼみに入れてから150分経過した時点(RSウィルスに感染してから90分経過した時点)のそのMDCK.2細胞の光学顕微鏡写真である。図6は、図1乃至図5すなわち実施例6にかかるMDCK.2細胞の顕微鏡写真を時系列に沿って示した図である。図1乃至図6特に図1と図2とに示されているように、MDCK.2細胞は、RSウィルスに感染した後、膨張し始めた。試料がかけられた後、一部のMDCK.2細胞が死滅したものの、大部分のMDCK.2細胞は正常に戻った。試料がかけられてから約10分後に細胞分裂が開始された。また、図5にも示されているように、試料がかけられてから約40分経過した時点で、膨張していた細胞がプレパラートの底に接着し、細胞の形態が正常に戻った。細胞数は減っていない。試料がかけられた後10分後にMDCK.2細胞が分裂を開始し、60分経過するまでに正常な形態に戻ることから、RSウィルスが死滅したものと考えられる。
(2) Observation Results FIG. 1 shows MDCK. 2 When the cells were placed in the collagen gel coat preparation indentation, the MDCK. It is an optical micrograph of 2 cells. FIG. 2 shows MDCK. 2 When 70 minutes have passed since the cells were placed in the preparation of the collagen gel coat preparation (when 10 minutes have passed since infection with the RS virus), the MDCK. It is an optical micrograph of 2 cells. FIG. 3 shows MDCK. 2 When 100 minutes have passed since the cells were placed in the preparation of the collagen gel coat preparation (when 40 minutes have passed after infection with the RS virus), the MDCK. It is an optical micrograph of 2 cells. FIG. 4 shows MDCK. 2 When 120 minutes have passed since the cells were put into the preparation of the collagen gel coat preparation (60 minutes after infection with the RS virus), the MDCK. It is an optical micrograph of 2 cells. FIG. 5 shows MDCK. The MDCK.2 at the time when 150 minutes have passed since the 2 cells were placed in the preparation of the collagen gel coat preparation (90 minutes after infection with the RS virus). It is an optical micrograph of 2 cells. FIG. 6 is a block diagram of MDCK. It is the figure which showed the microscope picture of 2 cells along the time series. As shown in FIGS. 1 to 6, particularly FIGS. 1 and 2, MDCK. Two cells began to swell after infection with the RS virus. After the sample is applied, some MDCK. Although 2 cells were killed, most MDCK. Two cells returned to normal. Cell division started approximately 10 minutes after the sample was applied. Also, as shown in FIG. 5, when about 40 minutes had passed after the sample was applied, the expanded cells adhered to the bottom of the preparation, and the cell morphology returned to normal. The number of cells has not decreased. 10 minutes after the sample was applied, MDCK. Since the two cells start dividing and return to a normal form by 60 minutes, it is considered that the RS virus has been killed.
[実施例7]
 (1) 試験手順
 作業者は、3本のメリンジョエキスチューブに収容されていた精製メリンジョエキス溶液と1本のビタミンチューブに収容されていた精製ビタミンEとを試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。この混合液が、本実施例にかかる試料である。したがって、本実施例にかかる試料の成分は、グネチンCが1.37重量%、レスベラトロールが0.44重量%、ジメチルスルホキシドが60.46重量%、ビタミンEが2.22重量%、水分が35.51重量%である。その他の点は実施例6と同様である。
[Example 7]
(1) Test procedure The operator puts 4.5 ml of purified merinjo extract solution contained in three meringo extract tubes and purified vitamin E contained in one vitamin tube in a test tube. Dissolved in dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. This mixed liquid is a sample according to this example. Therefore, the components of the sample according to this example are as follows: gnetin C 1.37% by weight, resveratrol 0.44% by weight, dimethyl sulfoxide 60.46% by weight, vitamin E 2.22% by weight, moisture Is 35.51% by weight. The other points are the same as in the sixth embodiment.
 (2) 観察結果
 MDCK.2細胞は、RSウィルスに感染した後、膨張し始めた。試料がかけられた後、ほぼすべてのMDCK.2細胞は正常に戻った。試料がかけられてから約10分後に細胞分裂が開始された。試料がかけられてから約60分後に細胞数が増え、形態が正常にもどることから、RSウィルスが死滅したと考えられる。
(2) Observation results MDCK. Two cells began to swell after infection with the RS virus. After the sample has been applied, almost all MDCK. Two cells returned to normal. Cell division started approximately 10 minutes after the sample was applied. About 60 minutes after the sample was applied, the number of cells increased and the morphology returned to normal, and it is considered that the RS virus had died.
[実施例8]
 (1) 試験手順
 作業者は、3本のメリンジョエキスチューブに収容されていた精製メリンジョエキス溶液と1本のビタミンチューブに収容されていた精製ビタミンEとを試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。次に、作業者は、その混合液にジメチルスルホキシド水溶液(ジメチルスルホキシドの濃度は63重量%)を加えた。これにより、その混合液の体積は2倍となった。グネチンCの濃度とレスベラトロールの濃度とビタミンEの濃度とは2分の1に希釈された。この混合液が、本実施例にかかる試料である。したがって、本実施例にかかる試料の成分は、グネチンCが0.69重量%、レスベラトロールが0.22重量%、ジメチルスルホキシドが61.72重量%、ビタミンEが1.11重量%、水分が36.26重量%である。その他の点は実施例6と同様である。
[Example 8]
(1) Test procedure The operator puts 4.5 ml of purified merinjo extract solution contained in three meringo extract tubes and purified vitamin E contained in one vitamin tube in a test tube. Dissolved in dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. Next, the worker added a dimethyl sulfoxide aqueous solution (the concentration of dimethyl sulfoxide was 63% by weight) to the mixed solution. Thereby, the volume of the liquid mixture was doubled. The concentrations of gnetin C, resveratrol, and vitamin E were diluted by half. This mixed liquid is a sample according to this example. Therefore, the components of the sample according to this example are as follows: gnetin C is 0.69% by weight, resveratrol is 0.22% by weight, dimethyl sulfoxide is 61.72% by weight, vitamin E is 1.11% by weight, moisture Is 36.26% by weight. The other points are the same as in the sixth embodiment.
 (2) 観察結果
 観察結果は実施例7と同様であった。
(2) Observation result The observation result was the same as that of Example 7.
[実施例9]
 作業者は、3本のメリンジョエキスチューブに収容されていた精製メリンジョエキス溶液と1本のビタミンチューブに収容されていた精製ビタミンEとを試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。次に、作業者は、その混合液にジメチルスルホキシド水溶液(ジメチルスルホキシドの濃度は63重量%)を加えた。これにより、その混合液の体積は4倍となった。グネチンCの濃度とレスベラトロールの濃度とビタミンEの濃度とは4分の1に希釈された。この混合液が、本実施例にかかる試料である。したがって、本実施例にかかる試料の成分は、グネチンCが0.34重量%、レスベラトロールが0.11重量%、ジメチルスルホキシドが62.36重量%、ビタミンEが0.56重量%、水分が36.63重量%である。その他の点は実施例6と同様である。
[Example 9]
The worker dissolves the purified meringo extract solution contained in three meringo extract tubes and the purified vitamin E contained in one vitamin tube in 4.5 ml dimethyl sulfoxide stock solution in a test tube. I let you. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. Next, the worker added a dimethyl sulfoxide aqueous solution (the concentration of dimethyl sulfoxide was 63% by weight) to the mixed solution. Thereby, the volume of the liquid mixture became 4 times. The concentrations of gnetin C, resveratrol and vitamin E were diluted by a factor of four. This mixed liquid is a sample according to this example. Therefore, the components of the sample according to the present example were 0.34% by weight of gnetin C, 0.11% by weight of resveratrol, 62.36% by weight of dimethyl sulfoxide, 0.56% by weight of vitamin E, moisture Is 36.63 wt%. The other points are the same as in the sixth embodiment.
 (2) 観察結果
 観察結果は実施例7と同様であった。
(2) Observation result The observation result was the same as that of Example 7.
[実施例10]
 作業者は、3本のメリンジョエキスチューブに収容されていた精製メリンジョエキス溶液と1本のビタミンチューブに収容されていた精製ビタミンEとを試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。次に、作業者は、その混合液にジメチルスルホキシド水溶液(ジメチルスルホキシドの濃度は63重量%)を加えた。これにより、その混合液の体積は8倍となった。グネチンCの濃度とレスベラトロールの濃度とビタミンEの濃度とは8分の1に希釈された。この混合液が、本実施例にかかる試料である。したがって、本実施例にかかる試料の成分は、グネチンCが0.17重量%、レスベラトロールが0.06重量%、ジメチルスルホキシドが62.68重量%、ビタミンEが0.28重量%、水分が36.81重量%である。その他の点は実施例6と同様である。
[Example 10]
The worker dissolves the purified meringo extract solution contained in three meringo extract tubes and the purified vitamin E contained in one vitamin tube in 4.5 ml dimethyl sulfoxide stock solution in a test tube. I let you. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. Next, the worker added a dimethyl sulfoxide aqueous solution (the concentration of dimethyl sulfoxide was 63% by weight) to the mixed solution. Thereby, the volume of the liquid mixture became 8 times. The concentrations of gnetin C, resveratrol, and vitamin E were diluted 1/8. This mixed liquid is a sample according to this example. Therefore, the components of the sample according to this example are 0.17% by weight of gnetin C, 0.06% by weight of resveratrol, 62.68% by weight of dimethyl sulfoxide, 0.28% by weight of vitamin E, moisture Is 36.81% by weight. The other points are the same as in the sixth embodiment.
 (2) 観察結果
 観察結果は実施例7と同様であった。
(2) Observation result The observation result was the same as that of Example 7.
[実施例11]
 (1) 試験手順
 (A) メリンジョエキスチューブの調製
 作業者は、以下の手順に従って本実施例にかかるメリンジョエキスチューブを調製した。まず、作業者は、メリンジョの果実を密封されたビンの中で55重量%のエチルアルコールに12時間漬けた。そのメリンジョは、果皮と果実と種子とが丸ごと粉砕されたものであった。そのメリンジョは乾燥品ではない生のメリンジョであった。メリンジョエキスチューブ1本分のメリンジョの果実の質量は50グラムであった。メリンジョエキスチューブ1本分のエチルアルコールの体積は500ミリリットルであった。そのメリンジョが漬けられている間、そのエチルアルコールの温度は摂氏90度に維持された。そのメリンジョが漬けられている間、そのエチルアルコールはスターラによって撹拌され続けられていた。12時間メリンジョがエチルアルコールに漬けられた後、作業者は、そのエチルアルコールからメリンジョの固形成分を除去した。そのエチルアルコールから固形成分が除去されると、作業者は、そのエチルアルコールを密封されたビンに入れた。作業者は、ポンプにそのビンの中の気体をビンの外へ排出させた。その際、そのビンの内部の温度は摂氏40度であった。気体の排気に伴い、そのビンの内部のエチルアルコールは蒸発した。作業者は、ビンの中に残った固形分30ミリリットルを所定のチューブに入れた。この固形分が収容されたチューブが本実施例におけるメリンジョエキスチューブである。
[Example 11]
(1) Test Procedure (A) Preparation of Melinjo Extract Tube The worker prepared a melinjo extract tube according to this example according to the following procedure. First, the worker dipped the Merinjo fruit in 55% by weight ethyl alcohol in a sealed bottle for 12 hours. The meringo was made by pulverizing the whole skin, fruit and seeds. The meringo was a raw meringo that was not dry. The mass of merinjo fruit for one meringo extract tube was 50 grams. The volume of ethyl alcohol for one meringo extract tube was 500 ml. While the meringo was soaked, the temperature of the ethyl alcohol was maintained at 90 degrees Celsius. While the meringo was soaked, the ethyl alcohol continued to be stirred by the stirrer. After 12 hours of immersing the Merinjo in ethyl alcohol, the worker removed the Merinjo's solid components from the ethyl alcohol. Once the solid component was removed from the ethyl alcohol, the operator placed the ethyl alcohol in a sealed bottle. The operator caused the pump to discharge the gas in the bottle out of the bottle. At that time, the temperature inside the bottle was 40 degrees Celsius. As the gas was evacuated, the ethyl alcohol inside the bottle evaporated. The operator put 30 ml of the solid content remaining in the bottle into a predetermined tube. The tube containing this solid content is the melinjo extract tube in this example.
 (B) 試料の調製
 作業者は、3本のメリンジョエキスチューブに収容されていた精製メリンジョエキス溶液と1本のビタミンチューブに収容されていた精製ビタミンEとを試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。この混合液が、本実施例にかかる試料である。したがって、本実施例にかかる試料の成分は、グネチンCが1.37重量%、レスベラトロールが0.44重量%、ジメチルスルホキシドが60.46重量%、ビタミンEが2.22重量%、水分が35.51重量%である。
(B) Preparation of sample The worker prepared 4.5 ml of purified melinjo extract solution contained in three meringo extract tubes and purified vitamin E contained in one vitamin tube in a test tube. In dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. This mixed liquid is a sample according to this example. Therefore, the components of the sample according to this example are as follows: gnetin C 1.37% by weight, resveratrol 0.44% by weight, dimethyl sulfoxide 60.46% by weight, vitamin E 2.22% by weight, moisture Is 35.51% by weight.
 (C) 細菌の培養
 まず、作業者は、米飯を素手で握ることによってその米飯の塊を形成した。米飯の塊が形成されると、作業者はその米飯の塊を1日放置した。米飯の塊が一日放置された後、作業者は、その米飯の塊を5g取り、pH7.4かつ7.5重量%塩化ナトリウム含有のリン酸緩衝生理食塩水PBS(希釈液)に混ぜ、すり潰した。作業者はそのすり潰された希釈液を卵黄添加マンニット食塩培地に塗りつけた。すり潰された米飯が卵黄添加マンニット食塩培地に塗りつけられると、作業者はその卵黄添加マンニット食塩培地を摂氏36度で48時間放置した。これにより、細菌のコロニーが形成された。卵黄添加マンニット食塩培地が48時間放置された後、作業者は、その卵黄添加マンニット食塩培地に形成された細菌のコロニーをリン酸緩衝生理食塩水100マイクロリットルに溶かした。この細菌のコロニーが溶けたリン酸緩衝生理食塩水が本実施例にかかる細菌試料である。
(C) Culture of bacteria First, the worker formed a lump of cooked rice by grasping the cooked rice with his bare hands. When the cooked rice lump was formed, the worker left the cooked rice lump for a day. After the lump of cooked rice was left for a day, the operator took 5 g of the lump of cooked rice and mixed it with phosphate buffered saline PBS (diluted solution) containing pH 7.4 and 7.5 wt% sodium chloride. Crushed. The operator smeared the ground diluted solution onto the egg yolk-added mannitol salt medium. When the ground rice was smeared on the egg yolk-added mannitol salt medium, the worker left the egg yolk-added mannitol salt medium at 36 degrees Celsius for 48 hours. Thereby, bacterial colonies were formed. After the yolk-added mannitol salt medium was left for 48 hours, the worker dissolved the bacterial colonies formed in the egg yolk-added mannitol salt medium in 100 microliters of phosphate buffered saline. The phosphate buffered saline in which the bacterial colonies are dissolved is a bacterial sample according to this example.
 (E) 細菌の観察
 まず、作業者は、プレパラートのくぼみにリン酸緩衝生理食塩水を20マイクロリットル入れた。そのくぼみにリン酸緩衝生理食塩水が20マイクロリットル入ると、作業者は、そのくぼみに20マイクロリットルの細菌試料を入れた。次に、作業者は、その細菌試料に本実施例にかかる試料をかけた。その後、作業者は、そのくぼみの中の細菌を光学顕微鏡で観察した。
(E) Observation of bacteria First, the operator put 20 microliters of phosphate buffered saline in the well of the preparation. When 20 microliters of phosphate buffered saline was placed in the well, the operator placed 20 microliters of bacterial sample in the well. Next, the worker applied the sample according to this example to the bacterial sample. Thereafter, the operator observed the bacteria in the recess with an optical microscope.
 (2) 観察結果
 細菌試料には、黄色ブドウ球菌および棹菌が含まれた。これらの細菌は、本実施例にかかる試料がかけられてから1時間経過した時点で、プレパラートのくぼみの底に沈んでいた。試料がかけられてから1時間後にすべての細菌が死滅した。
(2) Observation results The bacterial sample contained Staphylococcus aureus and Neisseria gonorrhoeae. These bacteria were sinking to the bottom of the preparation recess when one hour had passed since the sample according to this example was applied. All bacteria died 1 hour after the sample was applied.
[実施例12]
 (1) 試験手順
 本比較例においては、作業者は、9本のメリンジョエキスチューブに収容されていた精製メリンジョエキス溶液と1本のビタミンチューブに収容されていた精製ビタミンEとを試験管内で13.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は18ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。この混合液が、本実施例にかかる試料である。したがって、本実施例にかかる試料の成分は、グネチンCが4.11重量%、レスベラトロールが1.33重量%、ビタミンEが2.22重量%、ジメチルスルホキシドが58.17重量%、水分が34.17重量%である。試料の調製におけるその他の点と、細菌の培養の手順と、細菌の観察の手順とは実施例11と同様である。
[Example 12]
(1) Test procedure In this comparative example, the worker puts purified melinjo extract solution contained in nine meringo extract tubes and purified vitamin E contained in one vitamin tube in a test tube. In 13.5 milliliters of dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 18 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. This mixed liquid is a sample according to this example. Therefore, the components of the sample according to this example are 4.11% by weight of gnetin C, 1.33% by weight of resveratrol, 2.22% by weight of vitamin E, 58.17% by weight of dimethyl sulfoxide, and moisture. Is 34.17% by weight. Other points in the sample preparation, the bacterial culture procedure, and the bacterial observation procedure are the same as in Example 11.
 (2) 観察結果
 観察結果は実施例11と同様であった。
(2) Observation result The observation result was the same as that of Example 11.
[比較例1]
 (1) 試験手順
 作業者は、30本のメリンジョエキスチューブに収容されていた精製メリンジョエキス溶液(質量は60グラム)と1本のビタミンチューブに収容されていた精製ビタミンE(10ミリグラム)とを試験管内で45ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は60ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。この混合液が、本比較例にかかる試料である。したがって、本比較例にかかる試料の成分は、グネチンCが13.7重量%、レスベラトロールが4.4重量%、ジメチルスルホキシドが50.20重量%、ビタミンEが2.22重量%、水分が29.48重量%である。その他の点は実施例1と同様である。
[Comparative Example 1]
(1) Test procedure The operator made a purified melinjo extract solution (mass was 60 grams) contained in 30 meringo extract tubes and purified vitamin E (10 milligrams) contained in one vitamin tube. Were dissolved in 45 ml of dimethyl sulfoxide stock solution in a test tube. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 60 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example were as follows: gnetin C 13.7% by weight, resveratrol 4.4% by weight, dimethyl sulfoxide 50.20% by weight, vitamin E 2.22% by weight, moisture Is 29.48% by weight. Other points are the same as in the first embodiment.
 (2) 観察結果
 MDCK.2細胞は、H3N2に感染した後、膨張し始めた。MDCK.2細胞の細胞分裂は止まった。試料がかけられた後、MDCK.2細胞が次第に減少した。MDCK.2細胞の細胞分裂は観察されなかった。
(2) Observation results MDCK. Two cells began to swell after infection with H3N2. MDCK. The cell division of the two cells stopped. After the sample is applied, MDCK. Two cells gradually decreased. MDCK. No cell division of 2 cells was observed.
[比較例2]
 (1) 試験手順
 作業者は、3本のメリンジョエキスチューブに収容されていた精製メリンジョエキス溶液と1本のビタミンチューブに収容されていた精製ビタミンEとを試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。次に、作業者は、その混合液にジメチルスルホキシド水溶液(ジメチルスルホキシドの濃度は63重量%)を加えた。これにより、その混合液の体積は16倍となった。グネチンCの濃度とレスベラトロールの濃度とビタミンEの濃度とは16分の1に希釈された。この混合液が、本比較例にかかる試料である。したがって、本比較例にかかる試料の成分は、グネチンCが0.09重量%、レスベラトロールが0.06重量%、ジメチルスルホキシドが62.81重量%、ビタミンEが0.14重量%、水分が36.90重量%である。その他の点は実施例1と同様である。
[Comparative Example 2]
(1) Test procedure The operator puts 4.5 ml of purified merinjo extract solution contained in three meringo extract tubes and purified vitamin E contained in one vitamin tube in a test tube. Dissolved in dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. Next, the worker added a dimethyl sulfoxide aqueous solution (the concentration of dimethyl sulfoxide was 63% by weight) to the mixed solution. Thereby, the volume of the liquid mixture became 16 times. The concentrations of gnetin C, resveratrol and vitamin E were diluted 1/16. This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example were as follows: gnetin C 0.09% by weight, resveratrol 0.06% by weight, dimethyl sulfoxide 62.81% by weight, vitamin E 0.14% by weight, moisture Is 36.90% by weight. Other points are the same as in the first embodiment.
 (2) 観察結果
 MDCK.2細胞は、H3N2に感染した後、膨張し始めた。試料がかけられた後、MDCK.2細胞の形態に変化は見当たらなかった。MDCK.2細胞の分裂は見られず60分後に細胞数が減った。膨張した感染細胞も見られた。
(2) Observation results MDCK. Two cells began to swell after infection with H3N2. After the sample is applied, MDCK. There was no change in the morphology of the two cells. MDCK. Two cells did not divide and the number of cells decreased after 60 minutes. Swelled infected cells were also seen.
[比較例3]
 (1) 試験手順
 作業者は、3本のメリンジョエキスチューブに収容されていた精製メリンジョエキス溶液を試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。この混合液が、本比較例にかかる試料である。したがって、本比較例にかかる試料の成分は、グネチンCが1.37重量%、レスベラトロールが0.44重量%、ジメチルスルホキシドが61.86重量%、水分が36.33重量%である。その他の点は実施例1と同様である。
[Comparative Example 3]
(1) Test procedure The worker dissolved the purified melinjo extract solution contained in the three melinjo extract tubes in 4.5 ml of dimethyl sulfoxide stock solution in the test tube. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example are 1.37% by weight of gnetin C, 0.44% by weight of resveratrol, 61.86% by weight of dimethyl sulfoxide, and 36.33% by weight of water. Other points are the same as in the first embodiment.
 (2) 観察結果
 観察結果は比較例2と同様であった。
(2) Observation Result The observation result was the same as Comparative Example 2.
[比較例4]
(1) 試験手順
 作業者は、1本のビタミンチューブに収容されていた精製ビタミンE(10ミリグラム)を試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。この混合液が、本比較例にかかる試料である。したがって、本比較例にかかる試料の成分は、ビタミンEが2.22重量%、ジメチルスルホキシドが61.60重量%、水分が36.18重量%である。その他の点は実施例1と同様である。
(2) 観察結果
 観察結果は比較例2と同様であった。
[Comparative Example 4]
(1) Test procedure The worker dissolved purified vitamin E (10 milligrams) contained in one vitamin tube in 4.5 milliliters of dimethyl sulfoxide stock solution in a test tube. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example are 2.22% by weight of vitamin E, 61.60% by weight of dimethyl sulfoxide, and 36.18% by weight of water. Other points are the same as in the first embodiment.
(2) Observation Result The observation result was the same as Comparative Example 2.
[比較例5]
 (1) 試験手順
 (A) カテキンエキスチューブの調製
 作業者は、カテキンエキスチューブを調製した。「カテキンエキスチューブ」とは、後述される精製カテキンエキス溶液が後述される所定のチューブに収容されたものである。作業者は、以下の手順に従って本実施例にかかるカテキンエキスチューブを調製した。まず、作業者は、チャノキ(学名:Camellia sinensis (L.) Kuntze)の葉を摂氏110度で10分間焙煎した。カテキンエキスチューブ1本分のチャノキの葉の質量は50グラムであった。焙煎が終了すると、作業者は、焙煎されたチャノキの葉を密封されたビンの中で55重量%のエチルアルコールに24時間漬けた。カテキンエキスチューブ1本分のエチルアルコールの体積は500ミリリットルであった。そのチャノキの葉が漬けられている間、そのエチルアルコールの温度は摂氏90度に維持された。そのチャノキの葉が漬けられている間、そのエチルアルコールはスターラによって撹拌され続けられていた。24時間チャノキの葉がエチルアルコールに漬けられた後、作業者は、そのエチルアルコールの上清から未精製カテキンエキスを抽出した。未精製カテキンエキスの抽出には遠心エバポレータ(株式会社佐久間製作所製EC-57C)が用いられた。抽出時間は12時間であった。遠心エバポレータによって抽出された未精製カテキンエキスは乾燥した粉末状であった。未精製カテキンエキスが抽出されると、作業者は、その未精製カテキンエキスにジメチルスルホキシド水溶液(ジメチルスルホキシドの濃度は63重量%)を加え撹拌した。ジメチルスルホキシド水溶液の添加量は、未精製メリンジョエキスが抽出されたエチルアルコールの上澄5ミリリットルに対し、3ミリリットルであった。ジメチルスルホキシド水溶液が加えられ撹拌された未精製キテキンエキスが、本実施例における未精製カテキンエキス溶液である。撹拌が終了すると、作業者は、遠心分離機(Eppendorf社 Model 5415R)を用いることにより、その未精製カテキンエキス溶液から不純物を除去した。この遠心分離機の回転速度は15400rpmであった。この遠心分離機の使用時間は10分間であった。不純物が除去されたことにより、未精製キテキンエキス溶液は精製カテキンエキス溶液となった。作業者は、この精製カテキンエキス溶液2グラム(30ミリリットル)を所定のチューブに収容した。これが、カテキンエキスチューブである。
[Comparative Example 5]
(1) Test procedure (A) Preparation of catechin extract tube The operator prepared the catechin extract tube. The “catechin extract tube” is a tube in which a purified catechin extract solution described later is accommodated in a predetermined tube described later. The operator prepared the catechin extract tube according to this example according to the following procedure. First, the worker roasted leaves of Canoki (scientific name: Camellia sinensis (L.) Kuntze) at 110 degrees Celsius for 10 minutes. The weight of the leaves of one catechin extract tube was 50 grams. When the roasting was finished, the operator soaked the roasted chanoki leaves in 55% by weight ethyl alcohol in a sealed bottle for 24 hours. The volume of ethyl alcohol for one catechin extract tube was 500 ml. The temperature of the ethyl alcohol was maintained at 90 degrees Celsius while the leaves were pickled. The ethyl alcohol continued to be agitated by the stirrer while the leaf was pickled. After 24 hours of chanoki leaves were soaked in ethyl alcohol, the worker extracted unpurified catechin extract from the ethyl alcohol supernatant. A centrifugal evaporator (EC-57C manufactured by Sakuma Seisakusho Co., Ltd.) was used for extraction of the unpurified catechin extract. The extraction time was 12 hours. The unpurified catechin extract extracted by the centrifugal evaporator was a dry powder. When the crude catechin extract was extracted, the worker added an aqueous dimethyl sulfoxide solution (the concentration of dimethyl sulfoxide was 63% by weight) to the crude catechin extract and stirred. The amount of the aqueous dimethyl sulfoxide solution added was 3 ml with respect to 5 ml of the supernatant of ethyl alcohol from which the unpurified meringo extract was extracted. The unpurified catechin extract in which a dimethyl sulfoxide aqueous solution is added and stirred is the unpurified catechin extract solution in this example. When stirring was completed, the operator removed impurities from the unpurified catechin extract solution by using a centrifuge (Eppendorf Model 5415R). The rotational speed of this centrifuge was 15400 rpm. This centrifuge was used for 10 minutes. By removing the impurities, the unpurified Kitekin extract solution became a purified catechin extract solution. The operator accommodated 2 grams (30 milliliters) of this purified catechin extract solution in a predetermined tube. This is a catechin extract tube.
 (B) 試料の調製
 本比較例においては、作業者は、9本のカテキンエキスチューブに収容されていた精製カテキンエキス溶液と1本のビタミンチューブに収容されていた精製ビタミンEとを試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。この混合液が、本比較例にかかる試料である。したがって、本比較例にかかる試料の成分は、カテキンが16.80重量%、ビタミンEが2.22重量%、ジメチルスルホキシドが51.02%、水分が29.96重量%である。その他の点は実施例1と同様である。
(B) Preparation of sample In this comparative example, the worker puts purified catechin extract solution contained in nine catechin extract tubes and purified vitamin E contained in one vitamin tube in a test tube. Dissolved in 4.5 ml dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example are catechin 16.80% by weight, vitamin E 2.22% by weight, dimethyl sulfoxide 51.02%, and moisture 29.96% by weight. Other points are the same as in the first embodiment.
 (2) 観察結果
 MDCK.2細胞は、H3N2に感染した後、膨張し始めた。試料がかけられた後もMDCK.2細胞の状態に改善は見られず、60分後にMDCK.2細胞は順次死滅した。MDCK.2細胞に細胞分裂は観察されず、膨張した感染細胞も見られた。
(2) Observation results MDCK. Two cells began to swell after infection with H3N2. Even after the sample is applied, MDCK. There was no improvement in the state of the two cells, and MDCK. Two cells died sequentially. MDCK. No cell division was observed in 2 cells, and swollen infected cells were also observed.
 [比較例6]
 (1) 試験手順
 本比較例においては、作業者は、3本のカテキンエキスチューブに収容されていた精製カテキンエキス溶液を試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。この混合液が本比較例にかかる試料である。したがって、本比較例にかかる試料の成分は、カテキンが5.6重量%、ビタミンEが2.22重量%、ジメチルスルホキシドが58.17重量%、水分が34.11重量%である。その他の点は実施例1と同様である。
[Comparative Example 6]
(1) Test procedure In this comparative example, the operator dissolved the purified catechin extract solution contained in the three catechin extract tubes in 4.5 ml of a dimethyl sulfoxide stock solution in a test tube. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example are 5.6% by weight of catechin, 2.22% by weight of vitamin E, 58.17% by weight of dimethyl sulfoxide, and 34.11% by weight of water. Other points are the same as in the first embodiment.
 (2) 観察結果
 観察結果は比較例5と同様であった。
(2) Observation Result The observation result was the same as Comparative Example 5.
[比較例7]
 (1) 試験手順
 本比較例においては、作業者は、1本のビタミンチューブに収容されていた精製ビタミンE(10ミリグラム)を試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。この混合液が、本比較例にかかる試料である。したがって、本比較例にかかる試料の成分は、ビタミンEが2.22重量%、ジメチルスルホキシド61.6重量%、水分が36.18重量%である。その他の点は実施例1と同様である。
[Comparative Example 7]
(1) Test procedure In this comparative example, an operator dissolved purified vitamin E (10 milligrams) contained in one vitamin tube in 4.5 milliliters of a dimethyl sulfoxide stock solution in a test tube. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example are 2.22% by weight of vitamin E, 61.6% by weight of dimethyl sulfoxide, and 36.18% by weight of water. Other points are the same as in the first embodiment.
 (2) 観察結果
 観察結果は比較例2と同様であった。
(2) Observation Result The observation result was the same as Comparative Example 2.
[比較例8]
 (1) 試験手順
 作業者は、試料の調製にあたり、メリンジョエキスチューブ30本(精製メリンジョエキス溶液60グラム)と1本のビタミンチューブに収容されていた精製ビタミンE(10ミリグラム)とを試験管内で45ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は60ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。この混合液が、本比較例にかかる試料である。したがって、本比較例にかかる試料の成分は、グネチンCが13.7重量%、レスベラトロールが4.4重量%、ジメチルスルホキシドが50.20重量%、ビタミンEが2.22重量%、水分が29.48重量%である。その他の点は実施例6と同様である。
[Comparative Example 8]
(1) Test procedure When preparing the sample, the operator tested 30 meringo extract tubes (60 grams of purified meringo extract solution) and purified vitamin E (10 milligrams) contained in one vitamin tube. It was dissolved in 45 ml of dimethyl sulfoxide stock solution in a tube. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 60 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example were as follows: gnetin C 13.7% by weight, resveratrol 4.4% by weight, dimethyl sulfoxide 50.20% by weight, vitamin E 2.22% by weight, moisture Is 29.48% by weight. The other points are the same as in the sixth embodiment.
 (2) 観察結果
 MDCK.2細胞は、RSウィルスに感染した後、膨張し始めた。MDCK.2細胞の細胞分裂は止まった。試料がかけられた後、MDCK.2細胞が次第に減少した。MDCK.2細胞の細胞分裂は観察されなかった。
(2) Observation results MDCK. Two cells began to swell after infection with the RS virus. MDCK. The cell division of the two cells stopped. After the sample is applied, MDCK. Two cells gradually decreased. MDCK. No cell division of 2 cells was observed.
[比較例9]
 (1) 試験手順
 作業者は、3本のメリンジョエキスチューブに収容されていた精製メリンジョエキス溶液と1本のビタミンチューブに収容されていた精製ビタミンEとを試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。次に、作業者は、その混合液にジメチルスルホキシド水溶液(ジメチルスルホキシドの濃度は63重量%)を加えた。これにより、その混合液の体積は16倍となった。グネチンCの濃度とレスベラトロールの濃度とビタミンEの濃度とは16分の1に希釈された。この混合液が、本比較例にかかる試料である。したがって、本比較例にかかる試料の成分は、グネチンCが0.09重量%、レスベラトロールが0.06重量%、ジメチルスルホキシドが62.81重量%、ビタミンEが0.14重量%、水分が36.90重量%である。その他の点は実施例6と同様である。
[Comparative Example 9]
(1) Test procedure The operator puts 4.5 ml of purified merinjo extract solution contained in three meringo extract tubes and purified vitamin E contained in one vitamin tube in a test tube. Dissolved in dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. Next, the worker added a dimethyl sulfoxide aqueous solution (the concentration of dimethyl sulfoxide was 63% by weight) to the mixed solution. Thereby, the volume of the liquid mixture became 16 times. The concentrations of gnetin C, resveratrol and vitamin E were diluted 1/16. This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example were as follows: gnetin C 0.09% by weight, resveratrol 0.06% by weight, dimethyl sulfoxide 62.81% by weight, vitamin E 0.14% by weight, moisture Is 36.90% by weight. The other points are the same as in the sixth embodiment.
 (2) 観察結果
 MDCK.2細胞は、RSウィルスに感染した後、膨張し始めた。試料がかけられた後、MDCK.2細胞の形態に変化は見当たらなかった。膨張した感染細胞も見られた。
(2) Observation results MDCK. Two cells began to swell after infection with the RS virus. After the sample is applied, MDCK. There was no change in the morphology of the two cells. Swelled infected cells were also seen.
[比較例10]
 (1) 試験手順
 作業者は、3本のメリンジョエキスチューブに収容されていた精製メリンジョエキス溶液を試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は29ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は10ミリリットルであった。この混合液が、本比較例にかかる試料である。その他の点は実施例6と同様である。したがって、本比較例にかかる試料の成分は、グネチンCが1.37重量%、レスベラトロールが0.44重量%、ジメチルスルホキシドが61.86重量%、水分が36.33重量%である。
[Comparative Example 10]
(1) Test procedure The worker dissolved the purified melinjo extract solution contained in the three melinjo extract tubes in 4.5 ml of dimethyl sulfoxide stock solution in the test tube. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 29 ml. The volume of purified water in this dimethyl sulfoxide aqueous solution was 10 ml. This mixed liquid is a sample according to this comparative example. The other points are the same as in the sixth embodiment. Therefore, the components of the sample according to this comparative example are 1.37% by weight of gnetin C, 0.44% by weight of resveratrol, 61.86% by weight of dimethyl sulfoxide, and 36.33% by weight of water.
 (2) 観察結果
 MDCK.2細胞は、RSウィルスに感染した後、膨張し始めた。MDCK.2細胞の細胞分裂は止まった。試料がかけられた後、比較的な多くのMDCK.2細胞は正常に戻ったが、一部のMDCK.2細胞MDCK.2細胞は膨張したままだった。MDCK.2細胞の細胞分裂は生じなかった。
(2) Observation results MDCK. Two cells began to swell after infection with the RS virus. MDCK. The cell division of the two cells stopped. After the sample was applied, a relatively large number of MDCK. 2 cells returned to normal, but some MDCK. 2-cell MDCK. Two cells remained expanded. MDCK. Two-cell cell division did not occur.
[比較例11]
 (1) 試験手順
 作業者は、3本のカテキンエキスチューブに収容されていた精製カテキンエキス溶液と1本のビタミンチューブに収容されていた精製ビタミンEとを試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。この混合液が、本比較例にかかる試料である。したがって、本比較例にかかる試料の成分は、カテキンが5.6重量%、ビタミンEが2.22重量%、ジメチルスルホキシドが58.07重量%、水分が34.11重量%である。その他の点は実施例6と同様である。
[Comparative Example 11]
(1) Test procedure The worker used 4.5 ml dimethyl sulfoxide in a test tube of purified catechin extract solution contained in three catechin extract tubes and purified vitamin E contained in one vitamin tube. Dissolved in the stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example are 5.6% by weight of catechin, 2.22% by weight of vitamin E, 58.07% by weight of dimethyl sulfoxide, and 34.11% by weight of water. The other points are the same as in the sixth embodiment.
 (2) 観察結果
 観察結果は比較例9と同様であった。
(2) Observation Result The observation result was the same as Comparative Example 9.
[比較例12]
 (1) 試験手順
 作業者は、9本のカテキンエキスチューブに収容されていた精製カテキンエキス溶液と1本のビタミンチューブに収容されていた精製ビタミンEとを試験管内で13.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は18ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。この混合液が、本比較例にかかる試料である。したがって、本比較例にかかる試料の成分は、カテキンが16.80重量%、ビタミンEが2.22重量%、ジメチルスルホキシドが51.02重量%、水分が29.96重量%である。その他の点は実施例6と同様である。
[Comparative Example 12]
(1) Test procedure An operator uses 13.5 milliliters of dimethyl sulfoxide in a test tube with purified catechin extract solution contained in 9 catechin extract tubes and purified vitamin E contained in one vitamin tube. Dissolved in the stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 18 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example are catechin 16.80% by weight, vitamin E 2.22% by weight, dimethyl sulfoxide 51.02% by weight, and moisture 29.96% by weight. The other points are the same as in the sixth embodiment.
 (2) 観察結果
 観察結果は比較例2と同様であった。
(2) Observation Result The observation result was the same as Comparative Example 2.
[比較例13]
 (1) 試験手順
 本比較例の試料は比較例7のものと同一である。その他の点は実施例6と同様である。
[Comparative Example 13]
(1) Test procedure The sample of this comparative example is the same as that of the comparative example 7. The other points are the same as in the sixth embodiment.
 (2) 観察結果
 観察結果は比較例2と同様であった。
(2) Observation Result The observation result was the same as Comparative Example 2.
[比較例14]
 (1) 試験手順
 本比較例では、実施例1と同様の手順でMDCK.2細胞をコラーゲンゲルコートのプレパラートに入れた。MDCK.2細胞をそのプレパラートに入れてから60分が経過した後、作業者は、そのMDCK.2細胞に次に述べられる液体20マイクロリットルをかけた。その液体はRSウィルス(ATCC番号VR-1580)を含んでいた。これにより、そのMDCK.2細胞はRSウィルスに感染した。その後、そのMDCK.2細胞へは何もかけられなかった。RSウィルスを含む液体がかけられた後、作業者は、引続きMDCK.2細胞を光学顕微鏡で観察した。
[Comparative Example 14]
(1) Test Procedure In this comparative example, MDCK. Two cells were placed in a collagen gel coat preparation. MDCK. After 60 minutes have passed since the 2 cells were added to the preparation, the operator can then confirm the MDCK. Two cells were loaded with 20 microliters of the liquid described below. The liquid contained RS virus (ATCC number VR-1580). As a result, the MDCK. Two cells were infected with RS virus. Thereafter, the MDCK. Nothing was applied to the two cells. After the liquid containing the RS virus was applied, the worker continued to use MDCK. Two cells were observed with a light microscope.
 (2) 観察結果
 図7は本比較例にかかるMDCK.2細胞をコラーゲンゲルコートのプレパラートのくぼみに入れてから30分経過した時点のそのMDCK.2細胞の光学顕微鏡写真である。図8は本比較例にかかるMDCK.2細胞をコラーゲンゲルコートのプレパラートのくぼみに入れてから70分経過した時点(RSウィルスに感染してから10分経過した時点)のそのMDCK.2細胞の光学顕微鏡写真である。図9は本比較例にかかるMDCK.2細胞をコラーゲンゲルコートのプレパラートのくぼみに入れてから120分経過した時点(RSウィルスに感染してから60分経過した時点)のそのMDCK.2細胞の光学顕微鏡写真である。図10は本比較例にかかるMDCK.2細胞をコラーゲンゲルコートのプレパラートのくぼみに入れてから180分経過した時点(RSウィルスに感染してから120分経過した時点)のそのMDCK.2細胞の光学顕微鏡写真である。図11は、図7乃至図10すなわち比較例14にかかるMDCK.2細胞の顕微鏡写真を時系列に沿って示した図である。図7乃至図11に示されているように、MDCK.2細胞は、RSウィルスに感染した後、膨張し始めた。MDCK.2細胞の細胞分裂は止まった。
(2) Observation Results FIG. 7 shows MDCK. 2 When the cells were placed in the collagen gel coat preparation indentation, the MDCK. It is an optical micrograph of 2 cells. FIG. 8 shows MDCK. 2 When 70 minutes have passed since the cells were placed in the preparation of the collagen gel coat preparation (when 10 minutes have passed since infection with the RS virus), the MDCK. It is an optical micrograph of 2 cells. FIG. 9 shows MDCK. 2 When 120 minutes have passed since the cells were put into the preparation of the collagen gel coat preparation (60 minutes after infection with the RS virus), the MDCK. It is an optical micrograph of 2 cells. FIG. 10 shows MDCK. 2 When the 180 cells have passed since the cells were placed in the preparation of the collagen gel coat preparation (120 minutes after infection with the RS virus), the MDCK. It is an optical micrograph of 2 cells. FIG. 11 shows MDCK. It is the figure which showed the microscope picture of 2 cells along the time series. As shown in FIGS. 7 to 11, MDCK. Two cells began to swell after infection with the RS virus. MDCK. The cell division of the two cells stopped.
[比較例15]
 (1) 試験手順
 本比較例においては、作業者は、9本のカテキンエキスチューブに収容されていた精製カテキンエキス溶液と1本のビタミンチューブに収容されていた精製ビタミンEとを試験管内で13.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は18ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。この混合液が、本比較例にかかる試料である。したがって、本比較例にかかる試料の成分は、カテキンが16.80重量%、ビタミンEが2.22重量%、ジメチルスルホキシドが51.02重量%、水分が29.96重量%である。試料の調製におけるその他の点と、細菌の培養の手順と、細菌の観察の手順とは実施例11と同様である。
[Comparative Example 15]
(1) Test procedure In this comparative example, an operator can prepare a purified catechin extract solution contained in nine catechin extract tubes and a purified vitamin E contained in one vitamin tube in a test tube. Dissolved in 5 ml dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 18 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example are catechin 16.80% by weight, vitamin E 2.22% by weight, dimethyl sulfoxide 51.02% by weight, and moisture 29.96% by weight. Other points in the sample preparation, the bacterial culture procedure, and the bacterial observation procedure are the same as in Example 11.
 (2) 観察結果
 細菌は、試料がかけられてから2時間が経過した後も生存し、全滅しなかった。黄色ブドウ球菌の大部分は弱り死滅した。棹菌は死滅せず生き残っていた。
(2) Observation Results Bacteria survived after 2 hours from the application of the sample and did not disappear. Most of Staphylococcus aureus weakened and died. The gonococcus was not killed and survived.
[比較例16]
 (1) 試験手順
 本比較例においては、作業者は、3本のカテキンエキスチューブに収容されていた精製カテキンエキス溶液と1本のビタミンチューブに収容されていた精製ビタミンEとを試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。この混合液が、本比較例にかかる試料である。したがって、本比較例にかかる試料の成分は、カテキンが5.6重量%、ビタミンEが2.22重量%、ジメチルスルホキシドが58.07重量%、水分が34.11重量%である。試料の調製におけるその他の点と、細菌の培養の手順と、細菌の観察の手順とは実施例11と同様である。
[Comparative Example 16]
(1) Test procedure In this comparative example, the worker puts purified catechin extract solution contained in three catechin extract tubes and purified vitamin E contained in one vitamin tube in a test tube. Dissolved in 5 ml dimethyl sulfoxide stock solution. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example are 5.6% by weight of catechin, 2.22% by weight of vitamin E, 58.07% by weight of dimethyl sulfoxide, and 34.11% by weight of water. Other points in the sample preparation, the bacterial culture procedure, and the bacterial observation procedure are the same as in Example 11.
 (2) 観察結果
 観察結果は比較例15と同様であった。
(2) Observation Result The observation result was the same as that of Comparative Example 15.
[比較例17]
 (1) 試験手順
 本比較例においては、作業者は、1本のビタミンチューブに収容されていた精製ビタミンE(10ミリグラム)を試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。この混合液が、本比較例にかかる試料である。したがって、本比較例にかかる試料の成分は、ビタミンEが2.22重量%、ジメチルスルホキシドが61.6重量%、水分が36.18重量%である。試料の調製におけるその他の点と、細菌の培養の手順と、細菌の観察の手順とは実施例11と同様である。
[Comparative Example 17]
(1) Test procedure In this comparative example, an operator dissolved purified vitamin E (10 milligrams) contained in one vitamin tube in 4.5 milliliters of a dimethyl sulfoxide stock solution in a test tube. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example are 2.22% by weight of vitamin E, 61.6% by weight of dimethyl sulfoxide, and 36.18% by weight of water. Other points in the sample preparation, the bacterial culture procedure, and the bacterial observation procedure are the same as in Example 11.
 (2) 観察結果
 細菌は、試料がかけられてから2時間経過した時点において、黄色ブドウ球菌の形態にもその数にも何ら変化は見当たらなかった 。
(2) Observation Results Bacteria did not show any change in the form or number of Staphylococcus aureus at the time when 2 hours had passed since the sample was applied.
[比較例18]
 (1) 試験手順
 本比較例においては、作業者は、3本のカテキンエキスチューブに収容されていた精製カテキンエキス溶液を試験管内で4.5ミリリットルのジメチルスルホキシド原液に溶解させた。その後、作業者は、それらの混合液に精製水を添加した。精製水が添加された混合液の体積は6ミリリットルであった。作業者は、その混合液に、45ミリリットルのジメチルスルホキシド水溶液をさらに添加した。このジメチルスルホキシド水溶液のうちジメチルスルホキシドの体積は28ミリリットルであった。このジメチルスルホキシド水溶液のうち精製水の体積は17ミリリットルであった。この混合液が、本比較例にかかる試料である。したがって、本比較例にかかる試料の成分は、カテキンが5.6重量%、ジメチルスルホキシドが58.07重量%、ビタミンEが2.22重量%、水分が34.11重量%である。試料の調製におけるその他の点と、細菌の培養の手順と、細菌の観察の手順とは実施例11と同様である。
[Comparative Example 18]
(1) Test procedure In this comparative example, the operator dissolved the purified catechin extract solution contained in the three catechin extract tubes in 4.5 ml of a dimethyl sulfoxide stock solution in a test tube. Thereafter, the worker added purified water to the mixed solution. The volume of the mixed solution to which purified water was added was 6 ml. The operator further added 45 ml of a dimethyl sulfoxide aqueous solution to the mixture. Of this aqueous dimethyl sulfoxide solution, the volume of dimethyl sulfoxide was 28 ml. The volume of purified water in this aqueous dimethyl sulfoxide solution was 17 ml. This mixed liquid is a sample according to this comparative example. Therefore, the components of the sample according to this comparative example are 5.6% by weight of catechin, 58.07% by weight of dimethyl sulfoxide, 2.22% by weight of vitamin E, and 34.11% by weight of water. Other points in the sample preparation, the bacterial culture procedure, and the bacterial observation procedure are the same as in Example 11.
 (2) 観察結果
 観察結果は比較例15と同様であった。
(2) Observation Result The observation result was the same as that of Comparative Example 15.
[比較例19]
 本比較例では、実施例11で培養された細菌試料が用いられた。作業者は、細菌試料へ実施例11の説明にて記述されたリン酸緩衝生理食塩水20マイクロリットルのみをかけた。その後、作業者は、細菌試料の観察を行った。リン酸緩衝生理食塩水がかけられてから2時間経過した時点において、黄色ブドウ球菌の形態にもその数にも何ら変化は見当たらなかった。
[Comparative Example 19]
In this comparative example, the bacterial sample cultured in Example 11 was used. The operator applied only 20 microliters of phosphate buffered saline described in the description of Example 11 to the bacterial sample. Thereafter, the operator observed the bacterial sample. At 2 hours after the application of phosphate buffered saline, there was no change in the form or number of S. aureus.

Claims (4)

  1.  グネチンCと、
     レスベラトロールと、
     ビタミンEと、
     流動化物質とを含む抗生物質であって、
     前記グネチンCの重量%が0.17重量%以上4.11重量%以下であり、
     前記レスベラトロールの重量%が0.06重量%以上1.33重量%以下であり、
     前記ビタミンEの重量%が0.28重量%以上2.22重量%以下であることを特徴とする抗生物質。
    Gnetin C,
    With resveratrol,
    Vitamin E,
    An antibiotic containing a fluidizing substance,
    The weight% of the gnetin C is 0.17 wt% or more and 4.11 wt% or less,
    % By weight of the resveratrol is 0.06 wt% or more and 1.33 wt% or less,
    An antibiotic having a vitamin E content of 0.28 wt% or more and 2.22 wt% or less.
  2.  前記グネチンCの重量%が0.17重量%以上1.37重量%以下であり、
     前記レスベラトロールの重量%が0.06重量%以上0.44重量%以下であることを特徴とする請求項1に記載の抗生物質。
    The weight% of the gnetin C is 0.17 wt% or more and 1.37 wt% or less,
    The antibiotic according to claim 1, wherein a weight percent of the resveratrol is 0.06 wt% or more and 0.44 wt% or less.
  3.  前記グネチンCの重量%と前記レスベラトロールの重量%との和が0.23重量%以上1.81重量%以下であることを特徴とする請求項2に記載の抗生物質。 The antibiotic according to claim 2, wherein the sum of the weight% of the gnetin C and the weight% of the resveratrol is 0.23 wt% or more and 1.81 wt% or less.
  4.  前記グネチンCの重量%が0.17重量%以上0.69重量%以下であり、
     前記レスベラトロールの重量%が0.06重量%以上0.22重量%以下であることを特徴とする請求項1に記載の抗生物質。
    The weight% of the gnetin C is 0.17 wt% or more and 0.69 wt% or less
    The antibiotic according to claim 1, wherein a weight percent of the resveratrol is 0.06 wt% or more and 0.22 wt% or less.
PCT/JP2017/012319 2016-08-09 2017-03-27 Antibiotic WO2018029890A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016-156214 2016-08-09
JP2016156214A JP2018024592A (en) 2016-08-09 2016-08-09 Composition comprising antibiotic

Publications (1)

Publication Number Publication Date
WO2018029890A1 true WO2018029890A1 (en) 2018-02-15

Family

ID=61161918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/012319 WO2018029890A1 (en) 2016-08-09 2017-03-27 Antibiotic

Country Status (2)

Country Link
JP (1) JP2018024592A (en)
WO (1) WO2018029890A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114957A (en) * 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
WO2011001258A1 (en) * 2009-07-01 2011-01-06 Evita Life Science Pte. Ltd Compositions, methods, and kits for treating viral and bacterial infections by tocotrienols, tocomonoenols, tocodienols, tocopherols, and their derivates
JP2013051917A (en) * 2011-09-05 2013-03-21 Yamada Bee Farm Corp Trans-resveratrol containing composition
JP2014505705A (en) * 2011-02-02 2014-03-06 ザ トラスティーズ オブ プリンストン ユニヴァシティ Sirtuin modulators as virus production modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011981A (en) * 1999-05-24 2003-09-04 Sonus Pharma Inc Emulsion vehicle for poorly soluble drugs.
ITRM20020562A1 (en) * 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti USE OF THE RESVERATROL FOR THE PREPARATION OF A USEFUL DRUG FOR THE TREATMENT OF INFLUENCE VIRUS INFECTIONS.
JP2005023000A (en) * 2003-06-30 2005-01-27 Api Co Ltd Anti-bacterial agent and method for producing the same, and food preparation and antiseptic
EP1790239B1 (en) * 2004-09-14 2013-01-30 Hosoda SHC Inc. Gnetum extract
JP2010184886A (en) * 2009-02-12 2010-08-26 Hosoda Shc:Kk New compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114957A (en) * 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
WO2011001258A1 (en) * 2009-07-01 2011-01-06 Evita Life Science Pte. Ltd Compositions, methods, and kits for treating viral and bacterial infections by tocotrienols, tocomonoenols, tocodienols, tocopherols, and their derivates
JP2014505705A (en) * 2011-02-02 2014-03-06 ザ トラスティーズ オブ プリンストン ユニヴァシティ Sirtuin modulators as virus production modulators
JP2013051917A (en) * 2011-09-05 2013-03-21 Yamada Bee Farm Corp Trans-resveratrol containing composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAMPAGNA MICHELA ET AL.: "Antiviral activity of resveratrol", BIOCHEMIVAL SOCIETY TRANSACTIONS, vol. 38, no. 1, 1 August 2011 (2011-08-01), pages 50 - 53, XP055603079, ISSN: 0300-5127 *
CHAN, MARION MAN-YING: "Antimicrobial effect of resveratrol of on dermatophytes and bacterial pathogens of the skin", BIOCHEMICAL PHARMACOLOGY, vol. 63, no. 2, 15 January 2002 (2002-01-15), pages 99 - 104, XP055603080, ISSN: 0006-2952 *
KATO EISHIN ET AL.: "Stilbenoids Isolated from the Seeds of Melinjo (Gnetum gnemon L.) and Their Biological Activity", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 57, no. 6, 2009, pages 2544 - 2549, XP055233851, ISSN: 0021-8561, DOI: doi:10.1021/jf803077p *

Also Published As

Publication number Publication date
JP2018024592A (en) 2018-02-15

Similar Documents

Publication Publication Date Title
JP7097344B2 (en) Bismuth-thiol as a disinfectant for agricultural, industrial and other uses
Chacon et al. Inhibitory effects of microencapsulated allyl isothiocyanate (AIT) against Escherichia coli O157: H7 in refrigerated, nitrogen packed, finely chopped beef
CN107432834A (en) Antiseptic-free composition with antibacterial effect and preparation method and application thereof
CN109316536A (en) A kind of skin mucosa disinfecting agent and preparation method thereof
KR20160018648A (en) Composition for topical application comprising glycerol and tannins
KR102198872B1 (en) Centella asiatica aseptic aging solution with the skin calming and repair effects using a mineral and its Preparation method
Yang et al. Preparation of three-layer flaxseed gum/chitosan/flaxseed gum composite coatings with sustained-release properties and their excellent protective effect on myofibril protein of rainbow trout
JP2000136140A (en) Aqueous solution containing substance extracted from humic soil
JP3573941B2 (en) Composition having hyaluronidase inhibitory activity and cosmetic containing the composition
CN107582459A (en) A kind of preservative containing the capsule of weeping forsythia and preparation method thereof
CN108498436A (en) A kind of skin care bacteriostatic hand sanitizer and preparation method thereof
CN105199401B (en) A kind of edible antibacterial is replenished the calcium packaging film and preparation method thereof
BR112020003023A2 (en) compositions and methods for inhibiting plant pathogens
WO2018029890A1 (en) Antibiotic
CN105997561B (en) A kind of preparation method and purposes of casein-thyme essential oil liposome antibacterial agent
KR102229482B1 (en) Eryobotrya japonica leaf mineral sugar aging solution having a skin protecting effect and a method for producing the same
CN107951760A (en) A kind of natural anticorrosion compound of cosmetics and preparation method thereof
RU2363158C1 (en) Biocidal composition for soaking napkins
KR101076219B1 (en) Composition for suppressing production of biogenic amines
CN115298287B (en) Methanogenesis inhibitor composition and method for inhibiting methanogenesis
CN106635446B (en) A kind of biomembrane detergent and its preparation and application
CN108812637A (en) A kind of fur sample environment-friendly type ointment preservative and preparation method thereof
JP7432218B2 (en) Uses of primrose extracts
Sultanova et al. Features of biologically active substances of walnut shell
US20110311656A1 (en) Antimicrobial composition based on botanical extracts from oil palm vegetation liquor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17838966

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17838966

Country of ref document: EP

Kind code of ref document: A1